

# INDEX METHODOLOGY Solactive Pharma Breakthrough Value Index

Version 1.0 dated December 06, 2017



## **Contents**

## **Important Information**

## 1. Index specifications

- 1.1 Short Name and ISIN
- 1.2 Initial Value
- 1.3 Distribution
- 1.4 Prices and Calculation Frequency
- 1.5 Weighting
- 1.6 Index Committee
- 1.7 Publication
- 1.8 Historical Data
- 1.9 Licensing

# 2. Composition of the Index

- 2.1 Selection of the Index Components
- 2.2 Ordinary Adjustment
- 2.3 Extraordinary Adjustment

## 3. Calculation of the Index

- 3.1 Index Formula
- 3.2 Accuracy
- 3.3 Adjustments
- 3.4 Dividends and other Distributions
- 3.5 Corporate Actions
- 3.6 Correction Policy
- 3.7 Market Disruption
- 3.8 Consequences of an Extraordinary Event

## 4. Definitions

## 5. Appendix

- 5.1 Contact Details
- 5.2 Calculation of the Index Change in Calculation Method

## **Important Information**

This document ("Index Methodology Document") contains the underlying principles and regulations regarding the structure and the operating of the Solactive Pharma Breakthrough Value Index. Solactive AG shall make every effort to implement regulations. Solactive AG does not offer any explicit or tacit guarantee or assurance, neither pertaining to the results from the use of the Index nor the Index value at any certain point in time nor in any other respect. The Index is merely calculated and published by Solactive AG and it strives to the best of its ability to ensure the correctness of the calculation. There is no obligation for Solactive AG – irrespective of possible obligations to issuers – to advise third parties, including investors and/or financial intermediaries, of any errors in the Index. The publication of the Index by Solactive AG is no recommendation for capital investment and does not contain any assurance or opinion of Solactive AG regarding a possible investment in a financial instrument based on this Index.

This Index Methodology Document is to be used as the guidelines with regard to the composition, calculation and management of the Index. Any changes made to the Index Methodology Document are initiated by the Index Committee as defined in Section 1.6 Index Committee.

The Index is calculated and published by Solactive AG. The name "Solactive" is trademarked.

# 1. Index Specifications

The Solactive Pharma Breakthrough Value Index (the "Index") is an equity index owned by Solactive AG (the "Index Owner") and is calculated and distributed by Solactive AG (the "Calculation Agent").

The Index aims to track the performance of a basket of stocks of companies that are actively engaged in the research, development and/or manufacturing of orphan drugs. The index selects stocks of such companies that meet certain size and liquidity requirements, across various equity markets, using a two-fold approach that is primarily based on the trend in the valuation of a company's orphan drug portfolio and its net assets.

The Index is a net total return index, i.e. dividends are reinvested net of tax. The applicable withholding tax rates used to calculate the Net Total Return version can be accessed (under the title "Withholding Tax Rates") on the Calculation Agent's website at: http://www.solactive.com/news/documents/.

The price of the Index (the "Index Value") is calculated and published in US Dollars.

#### 1.1 Short Name and ISIN

The Index is distributed under ISIN DE000SLA30N4; the WKN is SLA3VV. The Index is published on Reuters under the RIC <.SOLBIOT> and on Bloomberg under the ticker <SOLBIOT Index>.

#### 1.2 Initial Value

The Index Value at the close of trading on the start date 09 March 2012 was set to be equal to a value of 100. The Index was officially launched on the Index Inception Date.

#### 1.3 Distribution

The Index is published via the price marketing services of Boerse Stuttgart AG and is distributed to all affiliated vendors. Each vendor decides on an individual basis as to whether they will distribute/display the Index via their information systems.

## 1.4 Prices and Calculation Frequency

The Index Value is calculated on each Business Day based on the prices of the relevant Index Components on the respective Exchanges on which they are listed. For the purposes of calculating the Index Value on a Business Day, the most recent prices of all relevant Index Components are used. Further, prices of Index Components not listed in the Index Currency are converted into the Index Currency using Reuters/WMCO closing mid spot exchange rates as at 4 pm London time. If such mid spot foreign exchange rate is unavailable on Reuters on any Business Day, the most recent mid spot foreign exchange rate published by Reuters/WMCO, as applicable, shall be used for the purposes of calculating the Index Value.

The Index Value is calculated on each Business Day from 9:00am to 10:30pm, CET. In the event that data cannot be provided to Reuters or to the pricing services of Boerse Stuttgart AG the Index cannot be distributed.

## 1.5 Weighting

On each Adjustment Day the Index Components are weighted in accordance with the methodology described in Section 2.2 Ordinary Adjustment.

## 1.6 Index Committee

A committee composed of staff from the Index Owner and shall be responsible for decisions regarding the composition of the Index as well as any amendments to the rules (in this document referred to as the "Index Committee"). The future composition of the Index shall be determined by the Index Committee on the Selection Days according to the methodology set out in Section 2.1 Selection of Index Components of this document. Upon the occurrence of any Extraordinary Event, the Index Committee, in its sole and absolute discretion, shall make decisions that may affect the composition of the Index and implement any necessary adjustments.

Members of the Index Committee may recommend changes to this Index Methodology Document and submit them to the Index Committee for approval.

#### 1.7 Publication

All specifications and information relevant for calculating the Index Value are made available on the webpage:

http://www.solactive.de and the relevant sub-page:

https://www.solactive.com/?s=Solactive%20Biotechnology&index=DE000SLA30N4.

#### 1.8 Historical Data

Historical data will be maintained from the launch of the Index on the Index Inception Date.

## 1.9 Licensing

Licences to use the Index as a benchmark for derivative instruments are issued to stock exchanges, banks, financial services providers and investment houses by the Index Owner.

#### 1.10 Index Universe

On each Selection Day that occurs in the month of March, the Index Universe shall be determined based on orphan drug related company data provided by EvaluatePharma as described below. On each Selection Day that occurs in the month of September, the Index Universe shall remain unchanged from the Index Universe determined on the immediately preceding Selection Day.

An "orphan drug" is a pharmaceutical product that has been developed specifically to treat rare diseases or disorders. The assignment of "orphan" status to any drugs developed to treat a rare disease is a matter of public policy in many countries and has resulted in medical breakthroughs that may not have otherwise been achieved due to the economics of drug research and development.

**"EvaluatePharma"** are an independent third-party provider of consensus forecasts of leading industry analysts and analysis of the pharmaceutical and biotechnology healthcare sectors providing exclusive and trusted market intelligence into global performance. They are a part of the Evaluate Group whose official website can be accessed through the url: <a href="https://www.evaluategroup.com">www.evaluategroup.com</a>. Evaluate Group is headquartered in London with staff in Europe, United States, Japan and India with over 85 analysts and about 150 employees globally. They serve over 200 clients globally and have thousands of users. Further information on their team of experts and analysts can be accessed through the url: <a href="http://www.evaluategroup.com/public/Expertise.aspx">http://www.evaluategroup.com/public/Expertise.aspx</a>.

EvaluatePharma maintain a database of global publically listed pharmaceutical and biotechnology companies which, as of 4th September 2017, contained 2,335 companies. They build their database from a drug level upwards; tagging drugs from the earliest possible stage in the development cycle (from research project, preclinical, phases I-III and marketed) to their relevant company, pharmaceutical class, diseases, mechanism of action and EphMRA code (among many other classifications).

As part of their data collection process, they identify drugs that have been granted 'Orphan Drug Status' by the three regulatory bodies that can provide this designation:

- 1. The US Food and Drug Administration (FDA): FDA Orphan Database: https://www.accessdata.fda.gov/scripts/opdlisting/oopd/
- 2. The European Medicines Agency (EMA): EMA Orphan Database: <a href="http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/orphan\_search.jsp">http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/orphan\_search.jsp</a>
- NIBIO Orphan Database: https://www.nibiohn.go.jp/shinko/orphan/english/index.html

To enhance this list of drugs with orphan designations, EvaluatePharma apply a further layer of analysis to produce a 'pure' orphan list, which includes the following criteria:

- First indication (disease) approved is for an orphan condition.
- Products expected to generate more than 25% of sales from their orphan indications. This has led to the
  exclusion of drugs such as Avastin, Enbrel, Herceptin, Humira and Remicade, all of which have orphan
  designations for indications contributing less than 25% of sales.
- Trial sizes; with smaller Phase III trials suggesting orphan status.
- Drug pricing, higher prices were taken as an indicator of orphan status.

Orphan drugs are then tagged to the relevant company that owns the intellectual property and marketing rights for them within the EvaluatePharma database.

To determine the Index Universe, EvaluatePharma produces a list of companies that are involved in Orphan Drugs by running a search query with the following criteria: publically listed companies with one or more drugs that have been granted an orphan designation and are either in development (R&D) or approved for marketing (orphan drugs that have been suspended or abandoned in R&D are not included).

From the above list of companies that form the Index Universe, EvaluatePharma then apply further analysis to show the following for each company for the purposes of this Index:

- Company name
- · Country where it is headquartered
- Total company revenues (current and forecast)
- Orphan drug revenues (current and forecast)
- Aggregate Net Present Values (NPV's) for orphan drugs
- Pipeline / portfolio analysis:
  - Count of orphan drugs in development
  - Count of non-orphan drugs in development
  - Count of approved/marketed orphan drugs
  - Count of approved/marketed non-orphan drugs

In addition to the above, EvaluatePharma publish an annual Orphan Drug report that provides a 5 year, forward-looking view of the key drugs, companies, market dynamics and growth drivers on the orphan drug/rare disease market. The Orphan Drug Report is publicly available and the 2017 edition can be downloaded from the web url: <a href="https://www.evaluategroup.com/orphandrug2017">www.evaluategroup.com/orphandrug2017</a>.

The report draws its data from the EvaluatePharma database, the three Orphan disease databases and various publicly available documents (including company reports and regulatory filings). The written analysis is provided by their in-house team of analysts, EP Vantage, who come from a variety of backgrounds including journalism, buy-side and sell-side analyst and strategy roles within large pharmaceutical companies.

Each year the report includes:

- Definitions of orphan drugs and rare diseases
- Financial incentives for companies that develop and market orphan drugs
- Evaluate's methodologies
- Worldwide Orphan Drug Sales (2000-2022)
- Top 100 USA Drug Cost per Patient per Year 2012-2016
- 2016: USA Revenue per Patient per Year for Top 20 Selling Orphan Drugs

- Worldwide Orphan Drug Sales in 2022: Top 20 Companies
- Worldwide Orphan Drug Sales in 2022 Excluding Oncology: Top 20 Companies
- 2022: Top 20 Selling Orphan Drugs in the World
- 2022: Top 10 Selling Orphan Drugs and Pipeline in Europe
- 2022: Top 20 Orphan R&D Products based on NPV
- USA, EU & Japan Orphan Designations per Year & Cumulative (1983-2016)

## 1.11 Orphan Drugs NPV Calculation

On each Selection Day, in respect of each company comprised within the Index Universe, EvaluatePharma determines and provides the Calculation Agent with the net present value of the company that is attributable to orphan drugs (the "**Orphan Drugs NPV**") for the purposes of calculating the index. This is determined as the sum of the discounted annual future cash flows attributable to orphan drugs.

For instance, as of the Index Inception Date, the Orphan Drugs NPV calculation estimates future sales and costs in three parts - (i) using analyst consensus forecasts up to 2022, (ii) using a projection of sales, costs and resulting cash flows beyond 2022 over the life of the product up to 2037, and (iii) applying a terminal growth methodology to calculate cash flows beyond 2037, known as the product's terminal value. A discount rate is then applied to all cash flows to express them as present values, which are summed up to calculated the Orphan Drugs NPV.

Mathematically it can be expressed as:

$$NPV = \sum_{t} \frac{CF_t}{(1+i)^t}$$

where:

t = time of the cash flow

i = applicable discount rate that is based on the company size as described below

 $CF_t$  = the estimated cash flow at time t

The discount rate applied to cash flows is based on the company size in order to reflect the different expected returns/risk assumptions associated with smaller companies and allow the use of weighted average cost of capital. The rates chosen are those typically used within industry and allowing us to factor in the company size and risk into valuation. As of the Index Inception Date, the discount rates used were:

- 6.5% for a large-cap company (i.e., market capitalization of over \$30bn)
- 9% for a mid-cap company (i.e., market capitalization between \$2.5bn \$30bn)
- 11.5% for a small-cap company (i.e., market capitalization between \$250m \$2.5bn)
- 14% for a micro-cap company (i.e., market capitalization between \$100m \$250m)
- 14% of a nano-cap company (i.e., market capitalization below \$100m)

Further information on the calculation of Orphan Drugs NPV is available upon request from the Calculation Agent.

# 2. Composition of the Index

### 2.1 Selection of the Index Components

This section sets out the methodology used to determine the initial composition of the Index and to make periodic adjustments to the composition of the Index.

In respect of each Selection Day, the Calculation Agent shall determine the Index Components in accordance with the methodology described below:

- 1. If such Selection Day occurs in the month of March, the Calculation Agent shall determine the securities that constitute the Index Universe in accordance with the methodology described in *Section 1.10 Index Universe*. And, if such Selection Day occurs in the month of September, the Index Universe shall be the same as the Index Universe determined on the immediately preceding Selection Day.
- 2. The Calculation Agent shall select the securities that are eligible for inclusion in the Index (the "**Eligible Securities**") from the Index Universe in the following manner:

A Security shall be deemed to be an Eligible Security if:

- a. it is listed on an Eligible Exchange;
- b. it has, as of the Selection Day, a Free Float Market Capitalization of at least USD 200 million, unless such Security is an existing Index Component, in which case, the Free Float Market Capitalization must be at least USD 150 million;
- c. its Three Month Average Daily Value Traded, as of the Selection Day, is at least USD 1,000,000; and
- d. the relevant company has at least one Marketed Orphan Drug and has an Orphan Drug Revenue Share that is greater than zero;
- 3. On each Selection Day, an Eligible Security shall be deemed to be an Index Component if, in respect of such Eligible Security:
  - a. the Orphan Drug Revenue Share is within the top two quartiles (i.e. the median) of the Orphan Drug Revenue Shares of all Securities that satisfy criteria 2.a 2.d above;
  - b. the relevant company has at least two (2) Marketed Orphan Drugs; and
  - c. the YoY NPV Change is greater than zero or the Estimated Book-Value Per Share is greater than the Book-Value Per Share.

Notwithstanding steps 1, 2 and 3 above, if the total number of Index Components is less than fifteen (15), then the above methodology shall be repeated without provision 3.a.

## 2.2 Ordinary Adjustment

The composition of the Index shall be adjusted on each Adjustment Day that is deemed to be a Rebalancing Day by the Calculation Agent.

Each Adjustment Day that occurs in the month of March and September shall be deemed to be a Rebalancing Day. In addition, if the Calculation Agent determines that the Index Component Weight of any Index Components is greater than 15% on any other Review Day, then the Adjustment Day that occurs immediately after such Review Day shall be deemed to be a Rebalancing Day.

In respect of each Selection Day immediately preceding such Adjustment Day that is a Rebalancing Day, each Index Component is weighted equally such that the total Index Component Weight of all Index Components is equal to 100%.

The composition of the Index shall be determined on each Selection Day in accordance with the methodology described in *Section 2.1 Selection of Index Components*. The Calculation Agent shall publish any changes made to the Index composition on the Selection Day and consequently with sufficient notice before the Adjustment Day.

## 2.3 Extraordinary adjustment

An extraordinary adjustment, if applicable, shall be triggered and applied in compliance with the rules set forth in the Solactive Guideline for Extraordinary Corporate Actions that is available for download at the web url: https://www.solactive.com/wp-content/uploads/2017/02/ECA-Solactive-Guideline.pdf.

## 3. Calculation of the Index

#### 3.1 Index Formula

The Index Value on a Business Day at the relevant time is calculated in accordance with the following formula:

$$Index_{t} = \sum_{i=1}^{n} \frac{(x_{i,t} \times p_{i,t} \times f_{i,t})}{D_{t}}$$

where:

 $x_{i,t}$  = Number of Total Shares of the Index Component i on Trading Day t

 $p_{i,t}$  = Price of Index Component i on Trading Day t

 $f_{i,t}$  = Foreign exchange rate to convert the Price of Index Component i on Trading Day t into

the Index Currency

 $D_t$  = Divisor on Trading Day t

In respect of the Start Date, the Divisor shall be calculated according to the following formula:

$$D_t = \frac{\sum_{i=1}^{n} (p_{i,t} \times f_{i,t} \times x_{i,t})}{100}$$

After the close of trading on each Adjustment Day t, the Divisor in respect of the immediately following Trading Day shall be calculated according to the following formula:

$$D_{t+1} = \frac{\sum_{i=1}^{n} (p_{i,t} \times f_{i,t} \times x_{i,t+1})}{\text{Index}_{t}}$$

where:

 $x_{i,t+1}$  = Number of Total Shares of the Index Component i in respect of the immediately preceding Selection Day

In respect of a Trading Day *t* that is (i) not an Adjustment Day and (ii) a day on which there are no Corporate Actions, then the Divisor shall be calculated according to the following formula:

$$D_t = D_{t-1}$$

where:

t-1 means the immediately preceding Business Day.

#### 3.2 Accuracy

In respect of each Business Day, the Index Value, rounded to two decimal places, shall be published on Reuters and Bloomberg.

Trading Prices and spot foreign exchange rates used to calculate the Index Value shall be rounded to six decimal places.

Divisors shall be rounded to six decimal places.

## 3.3 Adjustments

Indices need to be adjusted for systematic changes in prices once these become effective. This requires the new Number of Total Shares of the affected Index Component and the Divisor to be calculated on an ex-ante basis.

Following the Index Committee's decision, the Index is adjusted for distributions, capital increases and stock splits.

This procedure ensures that the first ex quote can be properly reflected in the calculation of the Index. This exante procedure assumes the general acceptance of the Index calculation formula as well as open access to the parameter values used. The calculation parameters are provided by the Calculation Agent.

#### 3.4 Dividends and other Distributions

Dividend payments and other distributions are included in the Index. They cause an adjustment of the Divisor. The new Divisor is calculated as follows:

$$D_{t+1} = D_t \times \frac{\sum_{i=1}^{n} (p_{i,t} \times f_{i,t} \times x_{i,t}) - (x_{i,t} \times y_{i,t} \times g_{i,t})}{\sum_{i=1}^{n} (p_{i,t} \times f_{i,t} \times x_{i,t})}$$

where:

 $p_{i,t}$  = Price of Index Component i on Trading Day t

 $f_{i,t}$  = Foreign exchange rate to convert the Price of Index Component i on Trading Day t into

the Index Currency

 $x_{i,t}$  = Number of Total Shares of the Index Component i on Trading Day t

 $y_{i,t}$  = Distribution of Index Component i with ex date t+1 multiplied by the Dividend

Correction

**Factor** 

 $g_{i,t}$  = Foreign exchange rate to convert the amount of the distribution of Index Component i on

Trading Day t into the Index Currency

 $D_t$  = Divisor on Trading Day t

 $D_{t+1}$  = Divisor on Trading Day t+1

## 3.5 Corporate Actions

#### 3.5.1 Principles

Following the announcement by an issuer of Index Components of the terms and conditions of a corporate action ("Corporate Action"), the Calculation Agent shall determine whether such corporate action has a dilutive, concentrative or similar impact on the price of the relevant Index Component.

If this should be the case, the Calculation Agent shall make the necessary adjustments that are deemed appropriate in order to take into account the dilutive, concentrative or similar impact on the price of the relevant Index Components and shall determine the date on which such adjustments shall come into effect.

Amongst other things, the Calculation Agent can take into account the adjustment made by an Affiliated Exchange as a result of the corporate action with regard to option and futures contracts on the respective share traded on this Affiliated Exchange.

### 3.5.2 Capital Increases

In the case of capital increases with ex-date t + 1 the Index is adjusted as follows:

$$x_{i,t+1} = x_{i,t} \times \frac{1+B}{1}$$

where:

 $x_{i,t+1}$  = Number of Total Shares of Index Component i on Trading Day t+1

 $x_{i,t}$  = Number of Total Shares of Index Component i on Trading Day t

B = Shares received for every share held

$$p_{i,t+1} = \frac{p_{i,t} + s \times B}{1 + B}$$

where:

 $p_{i,t+1}$  = Hypothetical Price of Index Component i on Trading Day t+1

 $p_{i,t}$  = Price of Index Component i on Trading Day t

s = Subscription Price in the Index Component currency

B = Shares received for every share held

$$D_{t+1} = D_t \times \frac{\sum_{i=1}^{n} (p_{i,t} \times f_{i,t} \times x_{i,t}) + \sum_{i=1}^{n} [(x_{i,t+1} \times p_{i,t+1} \times f_{i,t}) - (x_{i,t} \times p_{i,t} \times f_{i,t})]}{\sum_{i=1}^{n} (p_{i,t} \times f_{i,t} \times x_{i,t})}$$

where:

 $D_{i,t+1}$  = Divisor on Trading Day t+1

 $D_{i,t}$  = Divisor on Trading Day t

 $p_{i,t}$  = Price of Index Component i on Trading Day t

 $f_{i,t}$  = Foreign exchange rate to convert the Price of Index Component i on Trading Day t into

the Index Currency

 $x_{i,t}$  = Number of Total Shares of the Index Component i on Trading Day t

 $p_{i,t+1}$  = Hypothetical price of Index Component i on Trading Day t+1

 $x_{i,t+1}$  = Number of Total Shares of the Index Component i on Trading Day t+1

## 3.5.3 Share Splits

In the case of share splits with ex-date on Trading Day t+1, it is assumed that the prices change in ratio of the terms of the split. The new Number of Total Shares is calculated as follows:

$$x_{i,t+1} = x_{i,t} \times B$$

where:

 $x_{i,t+1}$  = Number of Total Shares of the affected Index Component on Trading Day t+1

 $x_{i,t}$  = Number of Total Shares of the affected Index Component on Trading Day t

B = Shares after the share split for every share held before the split

## 3.5.4 Stock Distributions

In the case of stock distributions with ex-date on Trading Day t+1, it is assumed that the prices change according to the terms of the distribution. The new Number of Total Shares is calculated as follows:

$$x_{i,t+1} = x_{i,t} \times (1+B)$$

where:

 $x_{i,t+1}$  = Number of Total Shares of the affected Index Component on Trading Day t+1

 $x_{i,t}$  = Number of Total Shares of the affected Index Component on Trading Day t

B = Shares received for every share held

## 3.6 Correction Policy

The Calculation Agent shall make the greatest possible effort to accurately calculate and maintain its indices. However, the occurrence of errors in the index determination process cannot be ruled out. In such cases, the Calculation Agent adheres to its publicly available Correction Policy which can be downloaded from the following url: <a href="https://www.solactive.com/news/documents/">https://www.solactive.com/news/documents/</a>.

## 3.7 Market Disruption

In periods of market stress, the Calculation Agent shall calculate the Index following predefined and exhaustive arrangements set out in its publicly available Disruption Policy which can be downloaded from the following url: https://www.solactive.com/news/documents/.

#### 3.8 Consequences of an Extraordinary Event

In respect of a Business Day on which an Extraordinary Event comes into effect, the Trading Price for an Index Component on such day shall be the last available market price for such Index Component quoted on the Exchange on the day the event came into effect (or, if a market price is not available for the day the event came into effect, the last available market price quoted on the Exchange on a day specified as appropriate by the Calculation Agent), as determined by the Calculation Agent, and this price is used as the Trading Price of the particular Index Component until the end of the day on which the composition of the Index is next set.

In the event of an Insolvency of an issuer of an Index Component the Index Component shall remain in the Index until the next Adjustment Day. As long as a market price for the affected Index Component is available on a Business Day, this shall be applied as the Trading Price for this Index Component on the relevant Business Day, as determined in each case by the Calculation Agent. If a market price is not available on a Business Day the Trading Price for this Index Component is set to zero. The Index Committee may also decide to eliminate the respective Index Component at an earlier point in time prior to the next Adjustment Day. The procedure in this case is identical to an elimination due to and Extraordinary Event.

## 4. Definitions

"Adjustment Day" means each day that occurs on the 2<sup>nd</sup> Friday of each calendar month, and if such day is not a Trading Day, the immediately following Trading Day.

"Affiliated Exchange" means, in respect of an Index Component, an exchange, a trading or quotation system on which options and futures contracts on the Index Component in question are traded, as specified by the Calculation Agent.

"Book-Value Per Share" means, in respect of a Security and a Selection Day, the book value (i.e., net asset value) of the relevant company divided by the total number of shares outstanding in the relevant share class, as published on the most recent annual company report and sourced using the FactSet Formula FF\_BPS.

"Business Day" means each calendar day other than Saturdays and Sundays.

"Calculation Agent" means Solactive AG or any other appropriately appointed successor in this function.

"Corporate Action" shall have the meaning as defined in Section 3.5.1. Principles.

"Daily Traded Value" means, in respect of a Security and of an Trading Day, the product of (i) the closing price of such Share (denominated in the Index Currency) as provided by the Exchange and (ii) the volume traded (measured as a number of Shares) of such Share on the Exchange during such Exchange Trading Day.

"Delisting" means, in respect of an Index Component, an event where the Exchange announces pursuant to the Exchange regulations that the listing of, the trading in or the issuing of public quotes on the Index Component at the Exchange has ceased immediately or will cease at a later date, for whatever reason (provided delisting is not because of a Merger or a Takeover bid), and the Index Component is not immediately listed, traded or quoted again on an exchange, trading or listing system, acceptable to the Calculation Agent.

**"Dividend Correction Factor"** is calculated as 1 minus the applicable withholding tax rate and/or other applicable tax rate currently prevalent in the respective country. The withholding tax rates are published at the webpage <a href="https://www.solactive.com/news/documents/">https://www.solactive.com/news/documents/</a> under 'Withholding Tax Rates' and are determined using publicly available information.

"Eligible Exchange" means an exchange listed under column 'Exchanges' in *Table 1: Eligible Exchanges* in Annex A.

"Estimated Book-Value Per Share" means, in respect of a Security and a Selection Day, the estimated book value (i.e., net asset value) of the relevant company divided by the total number of shares outstanding in the relevant share class, as estimated and provided by Thomson Reuters I/B/E/S Estimates who are an independent third-party financial data provider.

"EvaluatePharma" shall have the meaning as defined in Section 1.10 Index Universe.

**"Exchange"** (collectively "Exchanges") means, in respect of Index and an Eligible Security, the primary exchange where such Eligible Security has its primary listing. The Index Committee may decide to designate a different stock exchange as the "Exchange" in respect of an Eligible Security for tradability reasons, even if the relevant company is only listed there via a Stock Substitute.

"Extraordinary Event" means any of the following events:

- a Merger
- a Takeover bid
- a Delisting
- the Nationalisation of a company
- Insolvency.

"FactSet" is an independent third-party financial data provider.

"FactSet Formula" means the formula used to access specific financial data on the relevant software provided by FactSet.

"Free Float Market Capitalization" means, in respect of a Security and a Selection Day, the free float adjusted market capitalization of the relevant company. As at the date of this document Free Float Market Capitalization is calculated as the multiplication of the Free Float Percentage (as sourced from Thomson Reuters and calculated as Free Float Shares divided by Total Shares Outstanding) multiplied with the Market Capitalization in Index Currency of the share class as of the respective Selection Day.

"Index Committee" shall have the meaning as defined in Section 1.6 Index Committee.

"Index Component" means, in respect of a Selection Day, each Security that shall be included in the Index.

"Index Component Weight" means, in respect of a Selection Day and an Index Component, the weight determined in accordance with the methodology described in Section 2.2 Ordinary Adjustment.

"Index Currency" means the US Dollar (USD).

"Index Inception Date" means the date on which the Index was launched and is equal to December 07, 2017.

"Index Owner" means Solactive AG or any other appropriately appointed successor in this function.

"Index Universe" means, in respect of a Selection Day, all Securities in respect of companies that are actively engaged in the research, development and/or the manufacturing of orphan drugs and deemed to be as such by EvaluatePharma as described in Section 1.10 Index Universe. As of the Index Inception Date, the Index Universe consisted of stocks listed in Table 2 Index Universe in Annex B.

"Index Value" shall have a meaning as defined in Section 1. Index Specifications.

"Insolvency" occurs with regard to an Index Component if (A) all shares of the respective issuer must be transferred to a trustee, liquidator, insolvency administrator or a similar public officer as result of a voluntary or compulsory liquidation, insolvency or winding-up proceedings or comparable proceedings affecting the issuer of the Index Components or (B) the holders of the shares of this issuer are legally enjoined from transferring the shares.

"Marketed Orphan Drugs" means, in respect of a Security and a Selection Day, the Orphan Drugs that are currently manufactured and marketed by the relevant company as provided by EvaluatePharma based on the data published in the relevant company's most recent annual company report and cross referenced with three regulatory bodies (US Food and Drug Administration, European Medicines Agency and NIBIO Orphan databases).

"Merger" means, in respect of an Index Component, any of the following events:

- (i) a change in the security class or a conversion of this share class that results in a transfer or an ultimate definite obligation to transfer all the shares in circulation to another legal person,
- (ii) a merger (either by acquisition or through forming a new structure) or a binding obligation on the part of the issuer to exchange shares with another legal person (except in a merger or share exchange under which the issuer of this Index Component is the acquiring or remaining company and which does not involve a change in security class or a conversion of all the shares in circulation),
- (iii) a takeover offer, exchange offer, other offer or another act of a legal person for the purposes of acquiring or otherwise obtaining from the issuer 100% of the shares issued that entails a transfer or the irrevocable obligation to transfer all shares (with the exception of shares which are held and controlled by the legal person), or

(iv) a merger (either by acquisition or through forming a new structure) or a binding obligation on the part of the issuer of the share or its subsidiaries to exchange shares with another legal person, whereby the issuer of the share is the acquiring or remaining company and it does not involve a change in the class or a conversion of the all shares issued, but the shares in circulation directly prior to such an event (except for shares held and controlled by the legal person) represent in total less than 50% of the shares in circulation directly subsequent to such an event.

"Merger Date" means the date on which a Merger is concluded or the date specified by the Calculation Agent if such a date cannot be determined under the law applicable to the Merger.

"Nationalisation" means a process whereby all shares or the majority of the assets of the issuer of the shares are nationalised or are expropriated or otherwise must be transferred to public bodies, authorities or institutions.

"Orphan Drugs NPV" means, in respect of a Security and a Selection Day, the net present value of the relevant company that is attributable to Orphan Drugs, as calculated and provided by EvaluatePharma as described in Section 1.11 Orphan Drugs NPV Calculation.

"Orphan Drugs Revenue Share" means, in respect of a Security and a Selection Day, the total revenue of the relevant company that is attributable to Orphan Drugs expressed as a percentage of the total revenue of such company, as provided by EvaluatePharma based on the data published in the relevant company's most recent annual company report.

"Rebalancing Day" means a day on which the composition of the Index shall be adjusted.

"Review Day" means each day that occurs on the 1<sup>st</sup> Friday of each calendar month and if such day is not a Business Day, the immediately following Business Day.

"Security" means, in respect of a company, any common share that is actively traded on a stock exchange.

"Selection Day" means each day that occurs on the 1<sup>st</sup> Friday of March and 1<sup>st</sup> Friday of September, and if such day is not a Business Day, the immediately following Business Day.

"Stock Substitute" includes in particular American Depository Receipts (ADR) and Global Depository Receipts (GDR).

"Takeover bid" means a bid to acquire, an exchange offer or any other offer or act of a legal person that results in the related legal person acquiring as part of an exchange or otherwise more than 10% and less than 100% of the voting shares in circulation from the issuer of the Index Component or the right to acquire these shares, as determined by the Calculation Agent based on notices submitted to public or self-regulatory authorities or other information considered by the Calculation Agent to be relevant.

"Three Month Average Daily Traded Value" means, in respect of a Security and a Selection Day, the sum of daily traded value over a three month period immediately preceding such Business Day divided by the number of Trading Days that occur during such three month period. It is sourced using the FactSet Formula AVG(XP\_TURNOVER).

"Total Shares" is in respect of an Index Component and any given Business Day the number or fraction of shares included in the Index. It is calculated for any Index Component as the ratio of (A) the Index Component Weight of an Index Component multiplied by the Index value and the Divisor and (B) its Trading Price (converted into the index currency according to the principles laid out in Section 1.4 Prices and Calculation Frequency of this document).

"Trading Day" means, in respect of an Index, a day on which London Stock Exchange, New York Stock Exchange, Tokyo Stock Exchange and Deutsche Borse Xetra are all open for trading (subject to market disruption events), excluding days on which trading may be ceased prior to the normal Exchange closing time. The Calculation Agent is ultimately responsible as to whether a certain day is a Trading Day with regard to the Index or an Index Component or in any other connection relating to this document.

**"Trading Price**" means, in respect of a Trading Day and an Index component (subject to the provisions given above under "Extraordinary Events"), the closing price on such day determined in accordance with the Exchange regulations. If the Exchange has no closing price for an Index Component, the Calculation Agent shall determine the Trading Price and the time of the quote for the share in question in a reasonable manner.

**"YoY NPV Change"** means, in respect of a Security and a Selection Day, the relative change in the Orphan Drugs NPV since the Selection Day that occurred a year ago and calculated as (i) the Orphan Drugs NPV in respect of such Selection Day divided by the Orphan Drugs NPV in respect of the Selection Day that occurred a calendar year ago, minus (ii) one.

# 5. Appendix

#### **5.1 Contact Details**

## Information regarding the Index concept

Solactive AG

Guiollettstr. 54

60325 Frankfurt, Germany

Tel.: +49 69 719 160 00

epd@solactive.com

## 5.2 Calculation of the Index - Change in Calculation Method

The application by the Calculation Agent of the method described in this document is final and binding. The Calculation Agent shall apply the methodology described above for the composition and calculation of the Index. However it cannot be excluded that the market environment, supervisory, legal, financial or tax reasons may require changes to be made to this methodology.

The Calculation Agent may from time to time make changes to this document and the methodology used to calculate the Index, which it deems to be necessary and desirable in order to prevent obvious or demonstrable error or to remedy, correct or supplement incorrect terms and conditions. Despite any modifications and changes the Calculation Agent may make from time to time, it shall take all appropriate steps to ensure that the relevant calculation method is applied in a manner that is consistent with the methodology described above.

# **Annex A**

**Table 1: Eligible Exchanges** 

No.	Exchange Code	Exchange
1	NA	Equity Euronext Amsterdam Netherlands
2	FP	Equity Euronext Paris France
3	FH	Equity Helsinki Stock Exchange Finland
4	HK	Equity Hong Kong Stock Exchange China
5	KQ	Equity Korea Exchange Korea
6	LN	Equity London Stock Exchange United Kingdom
7	UQ	Equity Nasdaq Global Market United States
8	UW	Equity Nasdaq Global Select Market United States
9	UN	Equity New York Stock Exchange United States
10	NO	Equity Oslo Norway
11	VX	Equity SIX Swiss (formerly Virt-X Switzerland)
12	SW	Equity SIX Swiss Exchange Switzerland
13	SS	Equity Stockholm Stock Exchange Sweden
14	TT	Equity Taiwan Stock Exchange Taiwan
15	JT	Equity Tokyo Stock Exchange Japan
16	TO	Equity Toronto Stock Exchange Canada
17	GY	Equity Xetra Germany
18	LI	Equity London International Exchange
19	AH	Equity Australian Securities Exchange Australia
20	AV	Equity Vienna Stock Exchange Austria
21	NZ	Equity New Zealand Exchange
22	ID	Equity Irish Stock Exchange Ireland
23	DC	Equity NASDAQ OMX Copenhagen Denmark
24	SB	Equity Barcelona Stock Exchange Spain
25	SN	Equity Madrid Stock Exchange Spain
26	SQ	Equity Sociedad de Bolsas Spain
27	IM	Equity Borsa Italiana Italy
28	PL	Equity Euronext Lisbon Portugal
29	SP	Equity Singapore Exchange Singapore
30	BB	Equity Euronext Brussels Belgium

# **Annex B**

# **Table 2: Index Universe**

Table below shows the Index Universe as of the Index Inception Date.

MC	Company Name	ISIN	Exch Code	Company Name	ISIN	Exch Code
AB SCIENCE SA  ABBORT LABORATORIES  US00287Y1991  US  BIOVERATY IN C  US09078749191  US  BLUERIRNT MEDICILES CORP  US09078719191  US  BULDERIRNT MEDICILES CORP  US0907871919  US  BULDERIRNT MEDICILES CORP  US0907871919  US  BULDERIRNT MEDICILES CORP  US0007871919  US  BURDANAM PHARMACEUTICALS INC  US0007871919  US  CARPATE PHARMACEUTICALS INC  US0007871919  US  CERLIEAR PHARMACEUTICALS INC  US007871919  US  CERLIEAR PHARMACEUTICALS INC  US007871919  US  CERLIEAR PHARMACEUTICALS INC  US0007871919  US  CERLIEAR PHARMACEUTICALS SA  CHELSEA THERAPEUTICS INC  US0007871919  US  CERLIEAR PHARMACEUTICALS INC  US0007871919  US  US007871919  US  CERLIEAR PHARMACEUTICALS INC  US0007871919  US  US007871919  US007871919  US  US007871919  US  US007871919  US  US00787191919  US00787191919  US007871919191919191919191919191919191919191	зм со	US88579Y1010		BIOMARIN PHARMACEUTICAL INC	US09061G1013	
ABBOTH INC	4SC AG	DE000A14KL72	DE	BIOSPECIFICS TECHNOLOGIES	US0909311062	US
ABBVIEINC	AB SCIENCE SA	FR0010557264			DE0005227201	
NEPONA THERAPEUTICS INC   US0028971073   US   BLUEPRINT MEDICINIES CORP   US0902771091   US   RALPYAN NY   US00434411086   US   BRISTOL-MYERS SQUIBB CO   US1101221083   US   RACTELION LTD-REG   CH0010532478   CH010532478   CH010532478   CH010571074   US0057074071   US   RCTINIUM PHARMACEUTICALS INC   US00397491017   US   ECELIDEX THERAPEUTICS INC   US0078247082   US   US0087247082   US0	ABBOTT LABORATORIES					
RELYNX NV	ABBVIE INC					
US00434H1086						
ACORDA THERAPEUTICS INC         US00484M1062         US         BT F LC         GB0001001592         GB           ACTINIUM PHARMACEUTICALS INC         US00507W1071         US         CASI PHARMACEUTICALS INC         US14787U1097         US           ADURO BIOTECH INC         US007381.017         US         CASI PHARMACEUTICALS INC         US14188801016         US           ACEGERION PHARMACEUTICALS INC         US00778240282         US         CELLEDEX THERAPEUTICS INC         US15170201049         US           AECERION PHARMACEUTICALS INC         US0076751029         US         CELLEDEX THERAPEUTICS INC         US15170301097         US           AETERNA ZENTARIS INC         CA0079754028         US         CERULEAN PHARMACEUTICALS SA         US15170901098         US           KORIN INC         US00647X1046         US         US00647X1046         US         CHELLESA THERAPEUTICS INTERNA         US1632831098         US         US1632831099         US         US1632841099         US         US1632841099         US						
ACTELION LTD-REG						
ACTINIUM PHARMACEUTICALS INC						
ACTIVE BIOTECH AB ADURO BIOTECH INC US007381.0017 US0076242082 US CELLDEX THERAPEUTICS INC US0076781029 US CELLDEX THERAPEUTICS INC US0077781028 US CELLDEX THERAPEUTICS INC US0087776102 US CELLDEX THERAPEUTICS INC US008778103 US CELLDEX THERAPEUTICS INC US008778103 US CELLDEX THERAPEUTICS INC US009778103 US CELLDEX THERAPEUTICS INC US009778103 US CELLDEX THERAPEUTICS INC US009778103 US CHEAR THERAPEUTICS INC US00978103 US CHEAR THERAPEUTICS INC US00978707 US00978103 US CHEAR THERAPEUTICS INC US00978103 US00978707 US00978707 US00978707 US00978707 US00978707 US00978707 US009787						
ADURO BIOTECH INC US0076242092 US CELGENC PP US1510201049 US NEGERION PHARMACEUTICALS INC US0076721029 US CELSION CORP US15117810352 US CELLERA PHARMACEUTICALS INC US0076751029 US CERULEAN PHARMACEUTICALS INC US0084770561 US008478040 US0						
DVAMS  INC   US0076242082						
ALEGERION PHARMACEUTICALS INC						
AEOLUS PHARMACEUTICALS INC  LOS076561094  LS CEMPRA INC  LS0694767051  LS CFR PHARMACEUTICALS A  LS0694767051  LS CFR PHARMACEUTICALS A  LS0694771051  LS CFR PHARMACEUTICALS A  LS0694771051  LS CFR PHARMACEUTICALS A  LS0694771065  LS CFR PHARMACEUTICALS A  LS0694771065  LS CHINA MEDICAL SYSTEM HOLDING  LS0697281069  LS CHINA MEDICAL SYSTEM HOLDING  LS1634811074  LEXION PHARMACEUTICALS INC  LS0697281069  LS CHINA MEDICAL SYSTEM HOLDING  LS1634811074  LEXION PHARMACEUTICALS INC  LS0697281069  LS CHINA MEDICAL SYSTEM HOLDING  LS1634811074  LS163						
RETERNA ZENTARIS INC  LO00179254028  LOS CERULEAN PHARMACINC  LO00179254028  LOS CERPHARMACEUTICALS INC  LO00179254028  LOS CHELSEA THERAPEUTICS INTERNA  LOS CHELSEA THERAPEUTICS INC  LOS CHIMA MEDICIAL SYSTEM HOLDING  LOS CHELSEA THERAPEUTICS INC  LOS CHELSEA THE ABOUTT AND THE ADMITTANT AN						
AGIOS PHARMACEUTICALS INC	AETERNA ZENTARIS INC					
AGIOS PHARMACEUTICALS INC						
AKORN INC	AGIOS PHARMACEUTICALS INC	US00847X1046	US	CHELSEA THERAPEUTICS INTERNA		
USALEGERA LTD	AKARI THERAPEUTICS PLC-ADR	US00972G1085	GB	CHEMOCENTRYX INC	US16383L1061	US
ALEXION PHARMACEUTICALS INC	AKORN INC	US0097281069	US	CHINA MEDICAL SYSTEM HOLDING	KYG211081248	CN
ALFRESA HOLDINGS CORP  JP3126340003  JP  CLEVELAND BIOLABS INC  US1886602022  USALKERMES PLC  IE00B896V515  IE  CLINUVEL PHARMACEUTICALS ITD  AU000000CUV3  AU  ALLIANCE PHARMAP LC  GB0031030819  GB  CONCORDIA INTERNATIONAL CORP  US2183521028  US2485671077  CSL LTD  AU000000CUS3  AU  AUAMAG PHARMACEUTICALS INC  US00163041060  US  CONCORDIA INTERNATIONAL CORP  US1283521028  US2485671077  CSL LTD  AU000000CSLB  AU  AUMAG PHARMACEUTICALS INC  US00163041060  US  CUBIST PHARMACEUTICALS IC  US0311621009  US  CUBIST PHARMACEUTICALS INC  US0311621009  US  CUBIST PHARMACEUTICALS INC  US03152W1099  US  CURIS INC  US03152W1099  US  CURIS INC  US03152W1099  US  CURIS INC  US03243641070  US  CVTCACEL PHARMACEUTICALS INC  US03475V1017  US  CVTRX CORP  US23282W6067  US  APPILLED BIOSCIENCES INC  US03835T2002  CA  CATORINETRAPEUTICS INC  US03835T2002  CA  CATORINETRAPEUTICS INC  US03835T2002  CA  CATORINETRAPEUTICS INC  US03835T2002  CA  DELCATH SYSTEMS INC  US249081048  US  ARRADIA INC  US0462981035  US  DAIGH SANKYP CO LTD  JP3475350009  JP  ARRAY BIOPHARMA CUTICALS INC  US0462981035  US  DAIGH SANKYP CO LTD  KR7170900005  KR  RR7170900005  KR  RR7170900005  KR  RR7170900005  KR  RR71V19000005  RR  ARRAY BIOPHARMA CUTICALS INC  US0462981035  US  DAIGH SANKYP CO LTD  JP3541200006  JP  AGRIC PHARMACEUTICALS INC  US0462891035  US  ENDOYTE INC  US0462891035  US  ENDOYTE INC  US0462891035  US  ENDOYTE	ALCOBRA LTD				US1694911074	-
ALLERGAN PLC    E0084905467 US   CLOVIS ONCOLOGY INC   US1894641000 US   CONCRDIA INTERNATIONAL CORP   CA2065391027 CA   CA2065391027 US   CHIBST PHARMACEUTICALS INC   US20152481000 US   CUBIS TPHARMACEUTICALS ILC   US229671010 US   CUBIS TPHARMACEUTICALS ILC   US229671010 US   CUBIS TPHARMACEUTICALS ILC   US2316291015 US   CUBIS TPHARMACEUTICALS INC   US2315241099 US   CUBIS TPHARMACEUTICALS INC   US2316241009 US   CUBIS TPHARMACEUTICALS INC   US3347571017 US   CVCLACEL PHARMACEUTICALS INC   US3347571017 US   CVCLACEL PHARMACEUTICALS INC   US3347571017 US   CVTOKINIETICS INC   US23228260061 US   US338201007 US   CVTOKINIETICS INC   US23228260061 US   US338201007 US   CVTOKINIETICS INC   US23228260061 US   US338201007 US   CVTOKINIETICS INC   US23228260061 US   US3382013007 US   DAILCHI SYSTEMS INC   US23228260061 US   US23228260061 US   US4026891073 US   DAILCHI SYSTEMS INC   US2326819600 US   US40426891035 US   DAILCHI SYSTEMS INC   US246819030 US   US40426891035 US   US40426891035 US   US40426891035 US   US40426891035 US   US4042691035 US   US4042691035 US   US4042691036 U	ALEXION PHARMACEUTICALS INC					
ALLERGAN PLC  KCTAVIS GROUP HF  IS0000000420  IS  CONATUS PHARMACEUTICALS INC  US2060071088  US  ALLIANCE PHARMA PLC  GB0031030819  GB  CONCORDIA INTERNATIONAL CORP  CA20653P1027  CA  ALMIRALL SA  LENTYAM PHARMACEUTICALS INC  US0016301076  US  US0204301076  US  CONCEPT THERAPEUTICS INC  US2183521028  ALMIRAL SA  LENTYAM PHARMACEUTICALS INC  US0016301060  US  CTI BIOPHARMA CORP  US12268781071  US228781071  US228781071  US2318261010  US  CUMBERLAND PHARMACEUTICALS LLC  US2307701092  US  CUMBERLAND PHARMACEUTICALS  US2307701092  US  CUMBERLAND PHARMACEUTICALS  US2307701092  US  CUMBERLAND PHARMACEUTICALS  US2307701092  US  CUMBERLAND PHARMACEUTICALS  US2307701092  US  US2318261000  US  CVCLACEL PHARMACEUTICALS  US23282414099  US  US3037671097  US  US3037671099  US  CVCLACEL PHARMACEUTICALS  US23282800607  US  ANGIODYNAMICS INC  US0367413005  US  CYTORINETICS INC  US23282800607  US  APPILLED GENETIC TECHNOLOGIES  US03823V1070  US  CYTORITHERAPEUTICS INC  US03383V3078  US  DAILCHI SANKYO CO LTD  JP3475350009  JP  APTOSE BIOSCIENCES INC  CA0387911003  CA  DAILCHI SANKYO CO LTD  JP3475350009  JP  APTOSE BIOSCIENCES INC  US0338301007  US  CA0387911003  CA  DONG-A STC OL TD  WR77000640003  KR R710900005  KR R710909016  US  SASKA PHARMACEUTICALS INC  US04269E1073  US  DAILCHI SANKYO CO LTD  WR77000640003  KR R710900005  KR R7109090005  KR R7109090005  KR R7109090006  KR R7109090006  KR R7109090005  KR R7109090006  KR R710900006  KR R7109090006  KR R710909006  KR R710909006  KR R710909006  KR R710909006  KR R71090006  KR R7109						
ACTAVIS GROUP HF    S0000000420   IS   CONATUS PHARMACEUTICALS INC   US2060071088   US     ALLIANCE PHARMA PLC   GB0031030819   GB   CONCORDIA INTERNATIONAL CORP   CA20653P1027   CA     ALLIANCE PHARMACEUTICALS INC   US20243Q1076   US   CORCEPT THERAPEUTICS INC   US2183521028   US     ALLIVILAM PHARMACEUTICALS INC   US0043Q1076   US   CSL LTD   AU000000CSL8   AU     AUMAG PHARMACEUTICALS INC   US0016311060   US   CTI BIOPHARMA CORP   US12648L6011   US     AMBIET BIOSCIENCES CORP   US02318X1000   US   CUBIST PHARMACEUTICALS LLC   US2296781071   US     AMBIET BIOSCIENCES CORP   US0311621009   US   CUBIST PHARMACEUTICALS LLC   US2296781071   US     CUMBERLAND PHARMACEUTICALS INC   US03152W1099   US   CURIS INC   US23125841059   US     CUMBERLAND PHARMACEUTICALS INC   US2325444059   US     CUMBIET SINC   US033741071   US   CYTOKINETICS INC   US23283X204057   US     ANTHERA PHARMACEUTICALS INC   US033674U3005   US   CYTOKINETICS INC   US232838X20605   US     APPILLED GENETIC TECHNOLOGIES   US03363240700   US   CYTOKINETICS INC   US232838X20605   US     APPICUS BIOSCIENCES INC   US0336374070   US   CYTRX CORP   US2328286081   US     APPICUS BIOSCIENCES INC   US0336372002   CA   DELCATH SYSTEMS INC   US2498091048   US     ARBDISTOS BIOSCIENCES INC   US033637911003   CA   DONG-A SOCIO HOLDINGS CO LTD   JP3475350009   US     ARRADIGM CORP   US034680404   US   DEPOMED INC   US2499091048   US     ARRADIGM CORP   US034680404   US   DONG-A SOCIO HOLDINGS CO LTD   KR710700040003   KR     ARRAJO PHARMACEUTICALS INC   US0426891073   US   DONG-A ST CO LTD   US2561352038   IN     ARRAY BIOPHARMA INC   US0426891073   US   DONG-A ST CO LTD   US2561352038   US     ARRAJO PHARMACEUTICALS INC   US0462681073   US   DONG-A ST CO LTD   US267961082   US     ASTELLAS PHARMA INC   US0462681073   US   DONG-A ST CO LTD   US267961082   US     ASTERLAS PHARMACEUTICALS INC   US0462681073   US   EAGLE PHARMACEUTICALS INC   US0452671083   US     ASTERLAS PHARMACEUTICAL SINC   US04626810075   US   EAGLE PHARMACEUTICALS INC   US04526810000   US0454						
ALLIANCE PHARMA PLC    GB0031030819   GB   CONCORDIA INTERNATIONAL CORP   CA20663P1027   CA   ALMIRALI SA   ES0157097017   ES   CORCEPT THERAPEUTICS INC   US2183521028   US   ALMIRALI SA   US204321076   US   CSL LTD   AU0000000CSLB   AU   AMAG PHARMACEUTICALS INC   US00163U1060   US   CTI BIOPHARMA CORP   US12648L6011   US   AMBIBT BIOSCIENCES CORP   US02318X1000   US   CUBIST PHARMACEUTICALS ILC   US2296781071   US   AMGEN INC   US03152W1099   US   CUBIST PHARMACEUTICALS ILC   US2329671071   US   AMGES INC   US03152W1099   US   CUBIST PHARMACEUTICALS INC   US23258414059   US   ANGIGODYNAMICS INC   US03475V1017   US   CYCLACEL PHARMACEUTICALS INC   US23258414059   US   ANGIGODYNAMICS INC   US03475V1017   US   US0367430005   US   CYTORINETICS INC   US23282W6057   US   ANGIGODYNAMICS INC   US03475V1017   US   US0367430005   US   CYTORINETICS INC   US23282804052   US   APPILED GENETIC TECHNOLOGIES   US03832037070   US   CYTORI THERAPEUTICS INC   US2328286081   US   APPILED GENETIC TECHNOLOGIES   US03832037070   US   CYTORI THERAPEUTICS INC   US23283820402   US   APPILED GENETIC TECHNOLOGIES   US03832037070   US   CYTORI THERAPEUTICS INC   US23283820402   US   APPILED GENETIC TECHNOLOGIES   US03832037070   US   CYTORI THERAPEUTICS INC   US23283820402   US   APPILED GENETIC TECHNOLOGIES   US03832037070   US   CYTORI THERAPEUTICS INC   US2328382040   US   APPILED GENETIC TECHNOLOGIES   US03832037070   US   CYTORI THERAPEUTICS INC   US2328360801   US   APPILED GENETIC TECHNOLOGIES   US038321070   US   DAIICH ISANKYO CO LTD   US2328826081   US   ARABIDHAMACEUTICALS INC   US038321070   US   DAIICH ISANKYO CO LTD   US246619500   US   ARABIDHAMA CORP   US03835054004   US   DEPOMED INC   US246619500   US   ARRAVA BIOPHARMA CORP   US042681073   US   DONG-A ST CO LTD   KR7170900005   KR   ARRAVA BIOPHARMA INC   US042681073   US   DONG-A ST CO LTD   KR7170900005   KR   ARRAVA BIOPHARMA INC   US042681073   US   DORG-ROTORIES-ADR   US2561362038   IN     ARRAVA BIOPHARMA INC   US0426810107   US   ENDERORY INC   US269871050   US						
ALMIRALL SA ALNYLAM PHARMACEUTICALS INC US0016310160 US CTI BIOPHARMA CORP US12848.6011 US CTI BIOPHARMA CORP US22318X1000 US CUBIST PHARMACEUTICALS LLC US2296781071 US AMMGEN INC US0311521099 US CUBIST PHARMACEUTICALS LLC US2296781071 US AMMGEN INC US0311521099 US CUBIST PHARMACEUTICALS LLC US2296781071 US AMMGEN INC US0311521099 US CUBIST PHARMACEUTICALS LLC US2296781071 US AMMCEN INC US03152W1099 US CURIS INC US23125891015 US AMMCIDYNAMICS INC US034757V1017 US US034757V1017 US US034757V1017 US US034757V1017 US US034757V1017 US US034757V1017 US US03475V1017 US US0345V1017						
ALNYLAM PHARMACEUTICALS INC US00163U1060 US CSL LTD AU000000CSL8 AU AMAG PHARMACEUTICALS INC US0163U1060 US CUBIST PHARMACEUTICALS LLC US2236781071 US AMBEIT BIOSCIENCES CORP US02318X1000 US CUBIST PHARMACEUTICALS LLC US2236781071 US AMBEIN INC US03152W1099 US CUMBERLAND PHARMACEUTICALS US2307701092 US AMBEIN INC US03152W1099 US CUMBERLAND PHARMACEUTICALS INC US2307701092 US ANGES INC US03152W1099 US CURIST INC US2307701092 US ANGES INC US03152W1099 US CURIST INC US23258ZW6057 US ANGES INC US03475V1017 US CYTOKINETICS INC US23283X2042 US APPLIED GENETIC TECHNOLOGIES US0387201007 US CYTOKINETICS INC US23283X2042 US APPLIED GENETIC TECHNOLOGIES US0382011007 US CYTOKINETICS INC US23283X2042 US APPLIED BIOSCIENCES INC US03832V3078 US DAILCHI SANKYO CO LTD JP3475350009 JP APTOSE BIOSCIENCES INC US0385054004 US DEPOMED INC US2499081048 US ARADIGM CORP US0385054004 US DEPOMED INC US2499081048 US ARADIGM SIDPHARMA CORP US04033A1007 US DONG-A ST CO LTD KR7000640003 KR ARIAD PHARMACEUTICALS INC US0469311003 US DONG-A ST CO LTD KR7000640003 KR ARIAD PHARMACEUTICALS INC US0469341054 US DEPOMED INC US0426961073 US DONG-A ST CO LTD KR700064003 KR ARIAD PHARMACEUTICALS INC US0426961073 US DONG-A ST CO LTD KR700064003 KR ARIAD PHARMACEUTICALS US0426961073 US DONG-A ST CO LTD US0426961073 US DAILCHI SANKYO CO LTD US0426961073 US DAILCHI SANKYO CO LTD US0426961073 US DONG-A ST CO LTD US0426961073 US DAILCHI SANKYO CO LTD US0426961073 US DAILCHI SANKYO CO LTD US0426961073 US DONG-A ST CO LTD US0426961073 US DAILCHI SANKYO CO LTD US0426961073 US DAILCHI SANKYO CO LTD US0426961073 US DONG-A ST CO LTD US0426961090 US0426961073 US DAILCHI SANKYO CO LTD US0426961073 US DAILCHI SANKYO CO LTD US0426961090						
MAMGE PHARMACEUTICALS INC						
AMBIT BIOSCIENCES CORP  AMGEN INC  US0311621009  US  CUBIST PHARMACEUTICALS LLC  US2326781071  US  AMIGUS THERAPEUTICS INC  US03152W1099  US  CURIS INC  US03162W1099  US  CURIS INC  US2312E91015  US  AMIGUS THERAPEUTICS INC  US03152W1099  US  CYCLACEL PHARMACEUTICALS INC  US23254L4059  US  ANGIODYNAMICS INC  US03475V1017  US  CYTOKINETICS INC  US23282W6657  US  ANTHERA PHARMACEUTICALS INC  US03674U3005  US  CYTOKINETICS INC  US03320J1007  US  CYTOKINETICS INC  US03322W3078  US  CYTOKINETICS INC  US03322W3078  US  CYTOKINETICS INC  US03322W3078  US  CYTOKINETICS INC  US0332V3078  US  CYTOKINETICS INC  US0332V3078  US  DAILOHI SANKYO CO LTD  US0338054004  US  DEPOMED INC  US034875350009  JP  APTOSE BIOSCIENCES INC  CA03835T2002  CA  DELCATH SYSTEMS INC  US24681P5008  US  ARABIJUTUS BIOPHARMA CORP  US03385054004  US  DEPOMED INC  US0426991034  US  ARRAULE INC  US0426991034  US  DAILOH-A SOCIO HOLDINGS CO LTD  KR77170900005  KR  RR7170900005  KR  RR7170900						
AMGEINC  US03152W1099 US  CURIS INC  US03152W1099 US  CURIS INC  US03152W1099 US  CURIS INC  US03152W1099 US  CURIS INC  US03475V1017 US  CYTCLACEL PHARMACEUTICALS INC  US23252L4.0699 US  ANGIODYNAMICS INC  US03475V1017 US  CYTOKINETICS INC  US2328ZW6067 US  US2328ZW6067 US  ANTHERA PHARMACEUTICALS INC  US03475V1017 US  CYTOKINETICS INC  US2328ZW6067 US  CYTOKINETICS INC  US2328ZW6067 US  US2328ZW6067 US  CYTOKINETICS INC  US249981044 US  DAILCHI SANKYO CO LTD  JP3475350009 JP  DAILCHI SANKYO CO LTD  JP3475350009 JP  US24691080 US  CYTOKINETICS INC  US2499981048 US  DAILCHI SANKYO CO LTD  JP3475350009 JP  US24691080 US  CYTOKINETICS INC  US2499981048 US  DAILCHI SANKYO CO LTD  JP3475350009 JP  RAPTOSE BIOSCIENCES INC  US249981048 US  DAILCHI SANKYO CO LTD  JP3475350009 JP  KR7000640003 KR  RAPOSE BIOSCIENCES INC  US249981048 US  DAILCHI SANKYO CO LTD  JR7700006000 KR  RAPOSE BIOSCIENCES INC  US24999781082 US  DAICHI SANKYO CO LTD  JR770000600 KR  RAPOSE BIOSCIENCES INC  US24691033 US  DR. REDDY'S LABORATORIES-ADR  US266195008 US  SATELLAS PHARMACEUTICALS INC  US2468P1035 US  DYAX CORP  US26746E1038 US  DYAX CORP  US26746E1038 US  DYAX CORP  US2661P5008 US2699791082 US  SATELLAS PHARMACEUTICALS INC  US2699791082 US  SATELLAS PHARMACEUTICALS INC  US26997961082 US  SATELLAS PHARMACEUTICALS INC						
AMICUS THERAPEUTICS INC  ANGES INC  JP3127700007  JP  CYCLACEL PHARMACEUTICALS INC  US23252444059  US  ANGIODYNAMICS INC  US03674U3005  US  ANTHERA PHARMACEUTICALS INC  US03674U3005  US  ANTHERA PHARMACEUTICALS INC  US03825244009  US  ANTHERA PHARMACEUTICALS INC  US03674U3005  US  CYTOKINETICS INC  US23283K2042  US  APPLIED GENETIC TECHNOLOGIES  US03822011007  US  CYTRX CORP  US2328286061  US  APRICUS BIOSCIENCES INC  US03823293078  US  ANTHORA PHARMACOUTICALS INC  US0383572002  CA  DELCATH SYSTEMS INC  US24661P5008  US  ARADIGM CORP  US0385054004  US  DEPOMED INC  US24661P5008  US  ARADIGM CORP  US0385054004  US  DEPOMED INC  US2499081048  US  ARADIUS BIOPHARMA CORP  CA0387911003  CA  DONG-A SOCIO HOLDINGS CO LTD  KR71070900005  KR  ARRAY BIOPHARMA INC  US0426981057  US  DASKA PHARMACEUTICALS CO LTD  JP3541200006  JP  EAGLE PHARMACEUTICALS INC  US0468541037  US  ASTEALAS PHARMA INC  JP3942400007  JP  EAGLE PHARMACEUTICALS INC  US0468481035  US  SASTEALAS PHARMACEUTICALS  US  SASTEALAS PHARMACEUTICALS  US  US0468481035  US  SASTRAZENECA PLC  GB0009895292  GB  EMERGENT BIOSOLUTIONS INC  US22908901058  US  AVERIA BIOTHERAPEUTICS INC  US0465131078  US  ENDOCYTE INC  US22908901058  US  AVERIA BIOTHERAPEUTICS INC  US0465131078  US  ENDOCYTE INC  US2292801051  US2292801051  US  AVERIA BIOTHERAPEUTICALS  US05215111025  US  ENDOCYTE INC  US2292801051  US2292807105  US  AVERIA BIOTHERAPEUTICALS  US0535881090  US  EXPILIBLIS INC  US0535881090  US  EXPILIBLIS INC  US0535881090  US  EXPILIBLIS INC  US0536801007  US  EXPILIBLIS INC  US0536801007  US  EXPILIBLIS INC  US0536801007  US  EXPILIBLIS INC  US0536801007  US  EXPILIBLIS INC  US07177M1036  US  EXPILI						
ANGES INC JP3127700007 JP CYCLACEL PHARMACEUTICALS INC US23282W6057 US ANGIODYNAMICS INC US03475V1017 US CYTOKINETICS INC US23282W6057 US ANTHERA PHARMACEUTICALS INC US03674U3005 US CYTORI THERAPEUTICS INC US23283K2042 US APPLIED GENETIC TECHNOLOGIES US0382J01007 US CYTRX CORP US2328286081 US APRICUS BIOSCIENCES INC US03832Y3078 US DAILCHI SANKYO CO LTD JP3475350009 JP APTOSE BIOSCIENCES INC CA03835T2002 CA DELCATH SYSTEMS INC US24661P5008 US ARADIGM CORP US03385054004 US DEPOMED INC US24691P5008 US ARADIGM CORP US03385054004 US DEPOMED INC US2499981048 US ARADIGM CORP CA0387911003 CA DONG-A SOCIO HOLDINGS CO LTD KR7000640003 KR ARAIDA PHARMACEUTICALS INC US04269E1073 US DONG-A STO LTD KR7170900005 KR ARAIDA PHARMACEUTICALC O LTD JP34541200006 JP EAGLE PHARMACEUTICALS INC US04269X1054 US DYAX CORP US26746E1038 US ASTELLAS PHARMA INC US04269X1054 US DYAX CORP US26746E1038 US ASTEALAS PHARMACEUTICALS US0462481035 US EILILLY & CO US5324571083 US ASTEAZENECA PLC GB0009895292 GB EMERGENT BIOSOLUTIONS INC US2908901058 US ATARA BIOTHERAPEUTICS INC US0465131078 US ENDO INTERNATIONAL PLC IE00BJ3V9050 IE ATHERSYS INC US04744L1061 US ENDOCYTE INC US2926941025 US AUXILIUM PHARMACEUTICALS INC US05334D1072 US ENDOCYTE INC US2926941025 US AUXILIUM PHARMACEUTICALS INC US05314D1072 US ENDOCYTE INC US2926941025 US AUXILIUM PHARMACEUTICALS INC US05314D1072 US ENDOCYTE INC US2926901058 US AUXILIUM PHARMACEUTICALS INC US0536810007 US EYELIXIS INC US05334D1072 US EYETHERAPEUTICALS INC US05334D1072 US EYETHERAPEUTICALS INC US0536810007 US EYETHERAPEUTICALS INC US053681000 US EXELIXIS INC US0536810007 US EYETHERAPEUTICALS INC US053681000 US EXELIXIS INC US0536810007 US EYETHERAPEUTICALS INC US0536801007 US EYETHERAPEUTICALS INC US336801004 US EXELEXIS INC US336801004 US EXELE	AMICUS THERAPEUTICS INC					
ANTHERA PHARMACEUTICALS INC US03674U3005 US CYTORI THERAPEUTICS INC US23283K2042 US APPLIED GENETIC TECHNOLOGIES US0382U31007 US CYTRX CORP US2328286081 US APPLIED GENETIC TECHNOLOGIES US0382U31007 US CYTRX CORP US2328286081 US APRICUS BIOSCIENCES INC US03835T2002 CA DELCATH SYSTEMS INC US24661P5008 US ARADIGM CORP US0385054004 US DEPOMED INC US2499081048 US ARADIGM CORP US0385054004 US DEPOMED INC US2499081048 US ARADIGM CORP US0385054004 US DEPOMED INC US2499081048 US ARADIGM CORP US04093341007 US DONG-A ST CO LTD KR7107900005 KR ARIAD PHARMACEUTICALS INC US0426921073 US DNG-A ST CO LTD KR7107900005 KR ARQULE INC US0426921073 US DNG-A ST CO LTD KR7107900005 KR ARQULE INC US0426921073 US DNG-A ST CO LTD US2561352038 IN ARRAY BIOPHARMA INC US0426921073 US DYAX CORP US26746E1038 US ASTELLAS PHARMACEUTICALS US0426921073 US DYAX CORP US26746E1038 US ASTELLAS PHARMA INC US0426921073 US DYAX CORP US26746E1038 US ASTELLAS PHARMA INC US0426921073 US DYAX CORP US26746E1038 US ASTELLAS PHARMA INC US0426921073 US ELI LILLY & CO US5324571083 US ASTEALAS PHARMACEUTICALS US0462481035 US ELI LILLY & CO US5324571083 US ASTRAZENECA PLC GB0009895292 GB EMERGENT BIOSOLUTIONS INC US29089Q1058 US ATTARA BIOTHERAPEUTICS INC US04744L1061 US ENDO INTERNATIONAL PLC IE00BJ3V9050 IE ATHERSYS INC US04744L1061 US ENDO INTERNATIONAL PLC IE00BJ3V9050 US AURIS MEDICAL HOLDING AG US05334D1072 US ERYTECH PHARMA FR0011471135 FR AVEO PHARMACEUTICALS INC US0535881090 US EXELIXIS INC US0333801070 US EXELIXIS INC US0333801070 US EXPLIXIS INC US0333801070 US EXPLIXIS INC US03338001046 US BAXTER INTERNATIONAL INC US07177M1036 US FIVE PRIME THERAPEUTICS INC US03383001046 US BAXTER INTERNATIONAL INC US07177M1036 US FIVE PRIME THERAPEUTICS INC US3458381064 US BAXTER INTERNATIONAL INC US07177M1036 US FIVE PRIME THERAPEUTICS INC US3458381064 US BAXTER INTERNATIONAL INC US07177M1036 US FOREST LABORATORIES INC US3458381064 US BAXTER INTERNATIONAL INC US07187711029 US FOREST LABORATORIES INC US3458381064 US BAXTER INTERNATIONAL INC US0757711029 US FOREST LAB	ANGES INC	JP3127700007		CYCLACEL PHARMACEUTICALS INC	US23254L4059	US
APPLIED GENETIC TECHNOLOGIES US03820J1007 US CYTRX CORP US2328286081 US APRICUS BIOSCIENCES INC US03832V3078 US DAIICHI SANKYO CO LTD JP3475350009 JP APTOSE BIOSCIENCES INC CA03835T2002 CA DELCATH SYSTEMS INC US2499081048 US ARADIGM CORP US0385054004 US DEPOMED INC US2499081048 US ARBUTUS BIOPHARMA CORP CA03879J1003 CA DONG-A SOCIO HOLDINGS CO LTD KR7000640003 KR ARIAD PHARMACEUTICALS INC US04269E1073 US DONG-A SOCIO HOLDINGS CO LTD KR7107000005 KR ARRAULE INC US04269E1073 US DR. REDDY'S LABORATORIES-ADR US2561352038 IN ARRAY BIOPHARMA INC US04269X1054 US DYAX CORP US26746E1038 US ASKA PHARMACEUTICAL CO LTD JP3541200006 JP EAGLE PHARMACEUTICALS INC US2697961082 US ASTELLAS PHARMA INC JP3942400007 JP EISAI CO LTD JP3160400002 JP ASTEX PHARMACEUTICALS US04624B1035 US ELI LILLY & CO US5324571083 US ASTRAZENECA PLC GB0009885292 GB EMERGENT BIOSOLUTIONS INC US2908901058 US ATARA BIOTHERAPEUTICS INC US04744L1061 US ENDOCYTE INC US29269A1025 US AURIS MEDICAL HOLDING AG CH0249375764 CH IMMUNE PHARMACEUTICALS INC US29269A1025 US AUSPEX PHARMACEUTICALS INC US05334D1072 US ENDO INTERNATIONAL PLC IE00B3V9050 IE AVEX PHARMACEUTICALS INC US05334D1072 US ENDO INTERNATIONAL PLC US29428V1044 US AVEXIS INC US053681090 US EXELUXIS INC US29428V1044 US AVEXIS INC US0536601007 US EYEGATE PHARMACEUTICALS INC US3016101040 US AVEXIS INC US05336011007 US EYEGATE PHARMACEUTICALS INC US3157208087 US BASILEA PHARMACEUTICALS INC US07177M1036 US FYTECH PHARMA FR0011471135 FR AVEX PHARMACEUTICALS INC US07177M1036 US FYTECH PHARMA FR0011471135 FR BAYEA G-REG DE000BAY0017 DE FORTESS BIOTECH INC US3495801046 US BAXETR INTERNATIONAL INC US0718131099 US FOREST LABORATORIES INC US3458381064 US BAYEA RG-REG DE000BAY0017 DE FORTESS BIOTECH INC US3458301064 US BAYEA RG-REG DE000BAY0017 DE FORTESS BIOTECH INC US3450001094 US BELLEROPHON THERAPEUTICS INC US0787711029 US FRESENIUS SE & CO KGAA DE0005785604 DE BIOCEVEYS SCIENCES INTL US09062X1037 US GENVEC INC US37250B1044 IT BIOCGEN INC US37250B1044 US	ANGIODYNAMICS INC	US03475V1017	US	CYTOKINETICS INC	US23282W6057	US
APRICUS BIOSCIENCES INC  US03832V3078  US  DAIICHI SANKYO CO LTD  JP3475350009  JP APTOSE BIOSCIENCES INC  CA03835T2002  CA  DELCATH SYSTEMS INC  US24661P5008  US ARADIGM CORP  US0385054004  US  DEPOMED INC  US2499081048  US  ARBUTUS BIOPHARMA CORP  CA0387911003  CA  DONG-A SOCIO HOLDINGS CO LTD  KR71000640003  KR ARADIGH INC  US0426981073  US  DR. REDDY'S LABORATORIES-ADR  US2561352038  IN ARRAY BIOPHARMA INC  US0426991054  US  ASKA PHARMACEUTICAL CO LTD  JP3541200006  JP EAGLE PHARMACEUTICALS INC  US0426981035  US  SASTRAZENECA PLC  GB0009895292  GB EMERGENT BIOSOLUTIONS INC  US04744L1061  US  BIODENTERNATIONAL PLC  IE00BJ3V9050  IE AUSIEL INC  US045736764  CH  IMMUNE PHARMACEUTICALS INC  US29269941025  US  AUSPEX PHARMACEUTICALS INC  US05231111025  US  ENDO INTERNATIONAL PLC  IE00BJ3V9050  IE AUSPEX PHARMACEUTICALS INC  US0533401072  US  ENDOCYTE INC  US29428V1044  US  AUSPEX PHARMACEUTICALS INC  US0533401072  US  ERYTECH PHARMA  IRO  US29428V1044  US  BASILEA PHARMACEUTICALS INC  US0533401072  US  ERYTECH PHARMA  IRO  US29428V1044  US  BASILEA PHARMACEUTICALS INC  US0533401072  US  ERYTECH PHARMA  IRO  US29428V1044  US  BASILEA PHARMACEUTICALS INC  US0533401072  US  ERYTECH PHARMA  IRO  US29428V1044  US  BASILEA PHARMACEUTICALS INC  US0533401072  US  ERYTECH PHARMA  IRO  US30233M1071  US  BASILEA PHARMACEUTICALS INC  US0533401072  US  ERYTECH PHARMA  US30233M1071  US  BASILEA PHARMACEUTICALS INC  US0533401072  US  ERYTECH PHARMA  US30233M1071  US  BASILEA PHARMACEUTICALS INC  US0533401072  US  ERYTECH PHARMA  US30233M1071  US  BASILEA PHARMACEUTICALS INC  US05338001074  US  BASILEA PHARMACEUTICALS INC  US0533801077  US  BASILEA PHARMACEUTICALS INC  US0533800107  US  BASILEA PHARMACEUT	ANTHERA PHARMACEUTICALS INC	US03674U3005	US	CYTORI THERAPEUTICS INC	US23283K2042	US
APTOSE BIOSCIENCES INC  ARADIGM CORP  US0385054004  US  DEPOMED INC  US2499081048  US  ARABUTUS BIOPHARMA CORP  CA03879J1003  CA  DONG-A SOCIO HOLDINGS CO LTD  KR7000640003  KR  ARAULE INC  US04033A1007  US  DONG-A ST CO LTD  KR7170900005  KR  ARQULE INC  US04269E1073  US  DR. REDDY'S LABORATORIES-ADR  US2561352038  IN  ARRAY BIOPHARMA INC  US04269E1073  US  DYAX CORP  US26746E1038  US  ASKA PHARMACEUTICAL CO LTD  JP354120006  JP  EAGLE PHARMACEUTICALS INC  US2697961082  US  ASTEX PHARMA INC  JP3942400007  JP  EISAI CO LTD  JP3160400002  JP  ASTEX PHARMACEUTICALS  US04624B1035  US  ELI LILLY & CO  US5324571083  US  ASTRAZENECA PLC  GB0009895292  GB  EMERGENT BIOSOLUTIONS INC  US29089Q1058  US  ATHERSYS INC  US04744L1061  US  ENDO INTERNATIONAL PLC  IE00BJ3V9050  IE  AUXILIUM PHARMACEUTICALS INC  US05334D1072  US  AVEXIS INC  US0533681090  US  EXPIZYME INC  US03036811070  US  EXPIZYME INC  US03038M1071  US  BASILEA PHARMACEUTICALS INC  US0535881090  US  EXPIZYME INC  US03033M1071  US  BASILEA PHARMACEUTICALS INC  US0533681090  US  EXPIZYME INC  US03033M1071  US  BASILEA PHARMACEUTICALS INC  US0533681090  US  EXPIZYME INC  US03033M1071  US  BASILEA PHARMACEUTICALS INC  US0533681090  US  EXPIZYME INC  US03033M1071  US  BASILEA PHARMACEUTICALS INC  US0533681090  US  EXPIZYME INC  US03033M1071  US  BASILEA PHARMACEUTICALS INC  US0533681090  US  EXPIZYME INC  US03033M1071  US  BASILEA PHARMACEUTICALS INC  US0536601007  US  EYEGATE PHARMACEUTICALS  US03033M1071  US  BASILEA PHARMACEUTICALS INC  US0718711029  US  FORTRESS BIOTECH INC  US33830X1046  US  BASILEA PHARMACEUTICALS INC  US0718131099  US  FORTRESS BIOTECH INC  US334860Q1094  US  BIODELIVERY SCIENCES INTL  US09060X1037  US  GENNEC INC  US37246C40669  US	APPLIED GENETIC TECHNOLOGIES	US03820J1007			US2328286081	
ARADIGM CORP US0385054004 US DEPOMED INC US2499081048 US ARBUTUS BIOPHARMA CORP CA0387911003 CA DONG-A SOCIO HOLDINGS CO LTD KR71000640003 KR ARIAD PHARMACEUTICALS INC US04033A1007 US DONG-A SOCIO HOLDINGS CO LTD KR7107900005 KR ARQULE INC US04269E1073 US DR. REDDY'S LABORATORIES-ADR US2561352038 IN ARRAY BIOPHARMA INC US04269X1054 US DYAX CORP US26746E1038 US ASKA PHARMACEUTICAL CO LTD JP3541200006 JP EAGLE PHARMACEUTICALS INC US2697961082 US ASTEAL PHARMACEUTICALS US04624B1035 US ELI LILLY & CO US5324571083 US ASTRAZENECA PLC GB0009895292 GB EMERGENT BIOSOLUTIONS INC US29089Q1058 US ATARA BIOTHERAPEUTICS INC US0465131078 US ENDO INTERNATIONAL PLC IE00BJ3V9050 IE ATHERSYS INC US04744L1061 US ENDOCYTE INC US29269A1025 US AURIS MEDICAL HOLDING AG CH0249375764 CH IMMUNE PHARMACEUTICALS INC US05334D1072 US ERYTECH PHARMA CEUTICALS INC US05334D1072 US ERYTECH PHARMA FRO011471135 FR AVEO PHARMACEUTICALS INC US0533801007 US ERYTECH PHARMA FRO011471135 FR AVEO PHARMACEUTICALS INC US05336801000 US EXELIXIS INC US0533801007 US EXPENSIVE US0533801071 US ERYTECH PHARMA FRO011471135 FR AVEO PHARMACEUTICALS INC US0533801009 US EXPITED PHARMACEUTICALS US0303301071 US BASILEA PHARMACEUTICALS INC US053881090 US EXPITED PHARMACEUTICALS US0303301071 US EXPENSIVE US0533801071 US EXPENSIVE US0533801007 US EXPENSIVE US03033031071 US03333031046 US0342FR AG-REG US07177101036 US FIVE PRIME THERAPEUTICS INC US3345831064 US0342FR AG-REG US07177101036 US FOREST LABORATORIES INC US3345831064 US0342FR AG-REG US0718131099 US FOREST LABORATORIES INC US3345861064 US0342FR AG-REG US0718131099 US FRESENIUS SE & CO KGAA DE0005785604 DE BIODELIVERY SCIENCES INTL US0906011060 US GENTIUM-SRL US37250B1044 US03100FLIVERY SCIENCES INTL US0906011060 US GENTIUM-SRL US37250B1044 US03005ENINC US09062X1037 US GENVEC INC US37246C4069 US037246C40669 US037246C40669 US037246C40669 US037246C40669 US037246C4066	APRICUS BIOSCIENCES INC					
ARBUTUS BIOPHARMA CORP  CA03879J1003  CA  DONG-A SOCIO HOLDINGS CO LTD  KR7170900005  KR  ARIAD PHARMACEUTICALS INC  US04269E1073  US  DR. REDDY'S LABORATORIES-ADR  US2561352038  IN  ARRAY BIOPHARMA INC  US04269X1054  US  DYAX CORP  US2561352038  IN  DASTELLAS PHARMA INC  US04269X1054  US  DYAX CORP  EAGLE PHARMACEUTICALS INC  US2697961082  US  ASTELLAS PHARMA INC  JP3942400007  JP  EISAI CO LTD  JP3160400002  JP  ASTEX PHARMACEUTICALS  US04624B1035  US  ELI LILLY & CO  US5324571083  US  ATARA BIOTHERAPEUTICS INC  US0465131078  US  EMERGENT BIOSOLUTIONS INC  US29089Q1058  US  AURIS MEDICAL HOLDING AG  CH0249375764  CH  IMMUNE PHARMACEUTICALS INC  US04744L1061  US  EPIZYME INC  US04744L1061  US  EPIZYME INC  US0463131072  US  EXPLIXIS INC  US05334D1072  US  EXPLIXIS INC  US05334D1072  US  EXPLIXIS INC  US05366U1007  US  EXPLIXIS INC  US05366U1007  US  EXELIXIS INC  US05366U1007  US  EXPLIXIS INC  US05366U1007  US  EXPLIXIS INC  US0316720807  US  BAXALTA INC  US07177M1036  US  FOREST LABORATORIES-ADR  US0727200  US  ERSENIUS SE & CO KGAA  DE0005785604  DE  BIOGEN INC  US037246C4069  US  GENYEC INC  US37246C4069  US  GENYEC INC  US37246C4069  US  GENYEC INC  US37246C4069  US  CH  CH  CH  CH  CH  CH  CH  CH  CH  C						
ARIAD PHARMACEUTICALS INC  US04269E1073  US  DONG-A ST CO LTD  KR7170900005  KR ARGULE INC  US04269E1073  US  DR. REDDY'S LABORATORIES-ADR  US2661352038  IN ARRAY BIOPHARMA INC  US04269X1054  US  ASKA PHARMACEUTICAL CO LTD  JP3541200006  JP  EAGLE PHARMACEUTICALS INC  US2697961082  US  ASTELLAS PHARMA INC  JP3942400007  JP  EISAI CO LTD  JP3160400002  JP  ASTEX PHARMACEUTICALS  US04624B1035  US  ELI LILLY & CO  US26939961082  US  ASTRAZENECA PLC  GB0009895292  GB  EMERGENT BIOSOLUTIONS INC  US2908901058  US  ATARA BIOTHERAPEUTICS INC  US04744L1061  US  ENDO INTERNATIONAL PLC  US02969A1025  US  AUXIS MEDICAL HOLDING AG  CH0249375764  CH  IMMUNE PHARMACEUTICALS INC  US05334D1072  US  ERYTECH PHARMA  FR0011471135  FR  AVEO PHARMACEUTICALS INC  US05334D1072  US  EXELIXIS INC  US05336011007  US  EXELIXIS INC  US0316101040  US  BAXALTA INC  US07177M1036  US  BAXALTA INC  US07177M1036  US  BAXALTA INC  US0748711029  US  BAXALTA INC  US0748711029  US  BAXALTA INC  US0748711029  US  FOREST LABORATORIES-ADR  US37250B1044  US  BAYER AG-REG  DE000BAY0017  DE  FORTRESS BIOTECH INC  US34583301064  US  BASILEROPHON THERAPEUTICALS INC  US09062X1037  US  GENVEC INC  US37250B1044  IT  BIOGEN INC  US37250B1044  IT  BIOGEN INC  US37250B1044  US  GENVEC INC  US37250B1044  IT  BIOGEN INC  US37250B1044  IT  BIOGEN INC  US37246C4069  US						
ARQULE INC  US04269×1054  US 04269×1054  US DYAX CORP  US26746E1038  US ARKAY BIOPHARMA INC  US04269×1054  US DYAX CORP  US26746E1038  US ARKAY BIOPHARMA INC  US04269×1054  US DYAX CORP  US26746E1038  US ASKA PHARMACEUTICAL CO LTD  JP3541200006  JP EAGLE PHARMACEUTICALS INC  US2697961082  US ASTEX PHARMA INC  JP3942400007  JP EISAI CO LTD  JP3160400002  JP EISAI CO LTD  US0324571083  US ELI LILLY & CO  US3324571083  US ELI LILLY & CO  US29089Q1058  US ASTRAZENECA PLC  GB0009895292  GB EMERGENT BIOSOLUTIONS INC  US29089Q1058  US ENDO INTERNATIONAL PLC  IE00BJ3V9050  IE ENDOCYTE INC  US2926941025  US ENDOCYTE INC  US2926941025  US ENDOCYTE INC  US2926941025  US EPIZYME INC  US292428V1044  US ENDOCYTE INC  US292428V1044  US EPIZYME INC  US292428V1044  US ERYTECH PHARMA  FR0011471135  FR AVEO PHARMACEUTICALS INC  US05334D1072  US ERYTECH PHARMA  FR0011471135  FR AVEO PHARMACEUTICALS INC  US0535881090  US EXELIXIS INC  US03366U1007  US EYEGATE PHARMACEUTICALS  US03233M1071  US EYEGATE PHARMACEUTICALS  BAXILEA PHARMACEUTICA-REG  CH0011432447  CH  FIBROGEN INC  US31572Q8087  US  BAXILEA PHARMACEUTICALS INC  US07187131099  US FOREST LABORATORIES INC  US3458381064  US  BAXTER INTERNATIONAL INC  US0718711029  US FRESENIUS SE & CO KGAA  DE0005785604  DE 500CRYST PHARMACEUTICALS INC  US09062X1037  US GENMAB A/S  DK0010272202  DK  BIOGEN INC  US37246C4069  US						
ARRAY BIOPHARMA INC  ASKA PHARMACEUTICAL CO LTD  ASKA PHARMA INC  ASTELLAS PHARMA INC  JP3942400007  JP  EAGLE PHARMACEUTICALS INC  JP3160400002  JP  EISAI CO LTD  JP3160400002  EISAI CO LTD  JP3160400002  JP  EISAI CO LTD						
ASKA PHARMACEUTICAL CO LTD  ASTELLAS PHARMA INC  ASTELLAS PHARMA INC  ASTELLAS PHARMACEUTICALS  US04624B1035  US  BELI LILLY & CO  US5324571083  US  ASTRAZENECA PLC  GB0009895292  GB  EMERGENT BIOSOLUTIONS INC  US29089Q1058  US  ATARA BIOTHERAPEUTICS INC  US0465131078  US  ENDO INTERNATIONAL PLC  IE00BJ3Y9050  IE  ENDO INTERNATIONAL PLC  US29269A1025  US  AURIS MEDICAL HOLDING AG  CH0249375764  CH  IMMUNE PHARMACEUTICALS INC  US05211J1025  US  EPIZYME INC  US05334D1072  US  ERYTECH PHARMA  FR0011471135  FR  AVEO PHARMACEUTICALS INC  US0535881090  US  EXELIXIS INC  US05366U1007  US  EYEGATE PHARMACEUTICALS  US301610400  US  BASILEA PHARMACEUTICA-REG  CH0011432447  CH  FIBROGEN INC  US31572Q8087  US  BAXALTA INC  US07177M1036  US  FOREST LABORATORIES INC  US3458381064  US  BAXER AG-REG  DE000BAY0017  DE  FORTRESS BIOTECH INC  US37250B1044  IT  BIOGEN INC  US37250B1044  IT  BIOGEN INC  US37226C4069  US						
ASTELLAS PHARMA INC  JP3942400007  JP  EISAI CO LTD  JP3160400002  JP  ASTEX PHARMACEUTICALS  US04624B1035  US  ELI LILLY & CO  US5324571083  US  ASTRAZENECA PLC  GB0009895292  GB  EMERGENT BIOSOLUTIONS INC  US29089Q1058  US  ATARA BIOTHERAPEUTICS INC  US04744L1061  US  ENDO INTERNATIONAL PLC  IE00BJ3V9050  IE  ATHERSYS INC  US04744L1061  US  ENDOCYTE INC  US29269A1025  US  AURIS MEDICAL HOLDING AG  CH0249375764  CH  IMMUNE PHARMACEUTICALS INC  US05211J1025  US  EPIZYME INC  US29428V1044  US  AUSEN PHARMACEUTICALS INC  US05334D1072  US  ERYTECH PHARMA  FR0011471135  FR  AVEO PHARMACEUTICALS INC  US0535881090  US  EXELIXIS INC  US05366U1007  US  EYEGATE PHARMACEUTICALS  US30161Q1040  US  BASILEA PHARMACEUTICA-REG  CH0011432447  CH  FIBROGEN INC  US031572Q8087  US  BAYARLA INC  US07177M1036  US  FIVE PRIME THERAPEUTICS INC  US33830X1046  US  BAYARLA GREG  DE000BAY0017  DE  FORTRESS BIOTECH INC  US3458381064  US  BELLEROPHON THERAPEUTICS INC  US09062Y1037  US  GENTIUM-SRL  BIOGEN INC  US37250B1044  IT  BIOGEN INC  US37250B1044  IT  BIOGEN INC  US37250B1044  IT  BIOGEN INC  US37246C4069  US						
ASTEX PHARMACEUTICALS  ASTRAZENECA PLC  GB0009895292  GB  EMERGENT BIOSOLUTIONS INC  US29089Q1058  USATARA BIOTHERAPEUTICS INC  US0465131078  US  ENDO INTERNATIONAL PLC  IE00BJ3V9050  IE  ATHERSYS INC  US04744L1061  US  ENDOCYTE INC  US29269A1025  US  AURIS MEDICAL HOLDING AG  AUSPEX PHARMACEUTICALS INC  US05211J1025  US  EPIZYME INC  US05334D1072  US  ERYTECH PHARMA  FR0011471135  FR  AVEO PHARMACEUTICALS INC  US053568U1007  US  EXELIXIS INC  US05366U1007  US  EXELIXIS INC  US05366U1007  US  EYEGATE PHARMACEUTICALS  US30233M1071  US  BASILEA PHARMACEUTICA-REG  CH0011432447  CH  FIBROGEN INC  US07177M1036  US  FOREST LABORATORIES INC  US34960Q1094  US  BELLEROPHON THERAPEUTICS INC  US09063V1035  US  GENMAB A/S  BIODELIVERY SCIENCES INTL  US09060J1060  US  GENTIUM-SRL  US37250B1044  IT  BIOGEN INC  US37246C4069  US						
ASTRAZENECA PLC  GB0009895292  GB  EMERGENT BIOSOLUTIONS INC  US29089Q1058  US  ATARA BIOTHERAPEUTICS INC  US0465131078  US  ENDO INTERNATIONAL PLC  IE00BJ3V9050  IE  ENDOCYTE INC  US29269A1025  US  AURIS MEDICAL HOLDING AG  CH0249375764  CH  IMMUNE PHARMACEUTICALS INC  US05211J1025  US  EPIZYME INC  US29428V1044  US  AUXILIUM PHARMACEUTICALS INC  US05334D1072  US  ERYTECH PHARMA  FR0011471135  FR  AVEO PHARMACEUTICALS INC  US0535881090  US  EXELIXIS INC  US05366U1007  US  EYEGATE PHARMACEUTICALS  US30233M1071  US  BASAILEA PHARMACEUTICA-REG  CH0011432447  CH  FIBROGEN INC  US07177M1036  US  FIVE PRIME THERAPEUTICS INC  US33830X1046  US  BAYER AG-REG  DE000BAY0017  DE  FORTRESS BIOTECH INC  US3458381064  US  BELLEROPHON THERAPEUTICS INC  US0787711029  US  FRESENIUS SE & CO KGAA  DE0005785604  DE  BIOCRYST PHARMACEUTICALS INC  US09060X1037  US  GENMAB A/S  BIODELIVERY SCIENCES INTL  US09060X1037  US  GENTIUM-SRL  US37250B1044  IT  BIOGEN INC  US37246C4069  US						
ATARA BIOTHERAPEUTICS INC US0465131078 US ENDO INTERNATIONAL PLC IE00BJ3V9050 IE ATHERSYS INC US04744L1061 US ENDOCYTE INC US29269A1025 US AURIS MEDICAL HOLDING AG CH0249375764 CH IMMUNE PHARMACEUTICALS INC #N/A N/A US AUSPEX PHARMACEUTICALS INC US05211J1025 US EPIZYME INC US29428V1044 US AUXILIUM PHARMACEUTICALS INC US05334D1072 US ERYTECH PHARMA FR0011471135 FR AVEO PHARMACEUTICALS INC US0535881090 US EXELIXIS INC US30161Q1040 US AVEXIS INC US05366U1007 US EYEGATE PHARMACEUTICALS US30233M1071 US BASILEA PHARMACEUTICA-REG CH0011432447 CH FIBROGEN INC US31572Q8087 US BAXALTA INC US07177M1036 US FIVE PRIME THERAPEUTICS INC US33830X1046 US BAXTER INTERNATIONAL INC US0718131099 US FOREST LABORATORIES INC US3458381064 US BAYER AG-REG DE000BAY0017 DE FORTRESS BIOTECH INC US34960Q1094 US BELLEROPHON THERAPEUTICS INC US09658V1035 US GENMAB A/S DK0010272202 DK BIOCRYST PHARMACEUTICALS INC US09060J1060 US GENTIUM-SRL US37250B1044 IT BIOGEN INC US09062X1037 US GENVEC INC US37246C4069 US						
ATHERSYS INC US04744L1061 US ENDOCYTE INC US29269A1025 US AURIS MEDICAL HOLDING AG CH0249375764 CH IMMUNE PHARMACEUTICALS INC US05211J1025 US EPIZYME INC US29428V1044 US AUXILIUM PHARMACEUTICALS INC US05334D1072 US ERYTECH PHARMA FR0011471135 FR AVEO PHARMACEUTICALS INC US0535881090 US EXELIXIS INC US05366U1007 US EYEGATE PHARMACEUTICALS US30233M1071 US BASILEA PHARMACEUTICA-REG CH0011432447 CH FIBROGEN INC US31572Q8087 US BAXALTA INC US07177M1036 US FIVE PRIME THERAPEUTICS INC US33830X1046 US BAXTER INTERNATIONAL INC US0718131099 US FOREST LABORATORIES INC US3458381064 US BAYER AG-REG DE000BAY0017 DE FORTRESS BIOTECH INC US34960Q1094 US BELLEROPHON THERAPEUTICS INC US0787711029 US FRESENIUS SE & CO KGAA DE0005785604 DE BIOCRYST PHARMACEUTICALS INC US09058V1035 US GENMAB A/S DK0010272202 DK BIODELIVERY SCIENCES INTL US09060J1060 US GENTIUM-SRL US37250B1044 IT BIOGEN INC						
AURIS MEDICAL HOLDING AG CH0249375764 CH IMMUNE PHARMACEUTICALS INC US29428V1044 US AUSPEX PHARMACEUTICALS INC US05211J1025 US EPIZYME INC US29428V1044 US ERYTECH PHARMACEUTICALS INC US05334D1072 US ERYTECH PHARMA FR0011471135 FR AVEO PHARMACEUTICALS INC US0535881090 US EXELIXIS INC US05366U1007 US EYEGATE PHARMACEUTICALS US30233M1071 US BASILEA PHARMACEUTICA-REG CH0011432447 CH FIBROGEN INC US31572Q8087 US BAXALTA INC US07177M1036 US FIVE PRIME THERAPEUTICS INC US33830X1046 US BAXTER INTERNATIONAL INC US0718131099 US FOREST LABORATORIES INC US3458381064 US BAYER AG-REG DE000BAY0017 DE FORTRESS BIOTECH INC US34960Q1094 US BELLEROPHON THERAPEUTICS INC US0787711029 US FRESENIUS SE & CO KGAA DE0005785604 DE BIOCRYST PHARMACEUTICALS INC US09058V1035 US GENMAB A/S DK0010272202 DK BIODELIVERY SCIENCES INTL US09060J1060 US GENTIUM-SRL US37250B1044 IT BIOGEN INC						
AUSPEX PHARMACEUTICALS INC US05211J1025 US EPIZYME INC US29428V1044 US AUXILIUM PHARMACEUTICALS INC US05334D1072 US ERYTECH PHARMA FR0011471135 FR AVEO PHARMACEUTICALS INC US0535881090 US EXELIXIS INC US05366U1007 US EYEGATE PHARMACEUTICALS US30233M1071 US BASILEA PHARMACEUTICA-REG CH0011432447 CH FIBROGEN INC US31572Q8087 US BAXALTA INC US07177M1036 US FIVE PRIME THERAPEUTICS INC US33830X1046 US BAXTER INTERNATIONAL INC US0718131099 US FOREST LABORATORIES INC US3458381064 US BAYER AG-REG DE000BAY0017 DE FORTRESS BIOTECH INC US34960Q1094 US BELLEROPHON THERAPEUTICS INC US0787711029 US FRESENIUS SE & CO KGAA DE0005785604 DE BIOCRYST PHARMACEUTICALS INC US09058V1035 US GENMAB A/S DK0010272202 DK BIODELIVERY SCIENCES INTL US09060J1060 US GENTIUM-SRL US37250B1044 IT BIOGEN INC US09062X1037 US GENVEC INC US37246C4069 US	AURIS MEDICAL HOLDING AG					
AVEO PHARMACEUTICALS INC US0535881090 US EXELIXIS INC US30161Q1040 US AVEXIS INC US05366U1007 US EYEGATE PHARMACEUTICALS US30233M1071 US BASILEA PHARMACEUTICA-REG CH0011432447 CH FIBROGEN INC US31572Q8087 US BAXALTA INC US07177M1036 US FIVE PRIME THERAPEUTICS INC US33830X1046 US BAXTER INTERNATIONAL INC US0718131099 US FOREST LABORATORIES INC US3458381064 US BAYER AG-REG DE000BAY0017 DE FORTRESS BIOTECH INC US34960Q1094 US BELLEROPHON THERAPEUTICS INC US0787711029 US FRESENIUS SE & CO KGAA DE0005785604 DE BIOCRYST PHARMACEUTICALS INC US09058V1035 US GENMAB A/S DK0010272202 DK BIODELIVERY SCIENCES INTL US09060J1060 US GENTIUM-SRL US37250B1044 IT BIOGEN INC US09062X1037 US GENVEC INC US37246C4069 US	AUSPEX PHARMACEUTICALS INC	US05211J1025		EPIZYME INC		
AVEXIS INC US05366U1007 US EYEGATE PHARMACEUTICALS US30233M1071 US BASILEA PHARMACEUTICA-REG CH0011432447 CH FIBROGEN INC US31572Q8087 US BAXALTA INC US07177M1036 US FIVE PRIME THERAPEUTICS INC US33830X1046 US BAXTER INTERNATIONAL INC US0718131099 US FOREST LABORATORIES INC US3458381064 US BAYER AG-REG DE000BAY0017 DE FORTRESS BIOTECH INC US34960Q1094 US BELLEROPHON THERAPEUTICS INC US0787711029 US FRESENIUS SE & CO KGAA DE0005785604 DE BIOCRYST PHARMACEUTICALS INC US09058V1035 US GENMAB A/S DK0010272202 DK BIODELIVERY SCIENCES INTL US09060J1060 US GENTIUM-SRL US37250B1044 IT BIOGEN INC US09062X1037 US GENVEC INC US37246C4069 US	AUXILIUM PHARMACEUTICALS INC	US05334D1072	US	ERYTECH PHARMA	FR0011471135	FR
SASILEA PHARMACEUTICA-REG	AVEO PHARMACEUTICALS INC	US0535881090	US	EXELIXIS INC	US30161Q1040	
BAXALTA INC US07177M1036 US FIVE PRIME THERAPEUTICS INC US33830X1046 US BAXTER INTERNATIONAL INC US0718131099 US FOREST LABORATORIES INC US3458381064 US BAYER AG-REG DE000BAY0017 DE FORTRESS BIOTECH INC US34960Q1094 US BELLEROPHON THERAPEUTICS INC US0787711029 US FRESENIUS SE & CO KGAA DE0005785604 DE BIOCRYST PHARMACEUTICALS INC US09058V1035 US GENMAB A/S DK0010272202 DK BIODELIVERY SCIENCES INTL US09060J1060 US GENTIUM-SRL US37250B1044 IT BIOGEN INC US09062X1037 US GENVEC INC US37246C4069 US	AVEXIS INC	US05366U1007	US	EYEGATE PHARMACEUTICALS	US30233M1071	
BAXTER INTERNATIONAL INC US0718131099 US FOREST LABORATORIES INC US3458381064 US BAYER AG-REG DE000BAY0017 DE FORTRESS BIOTECH INC US34960Q1094 US BELLEROPHON THERAPEUTICS INC US0787711029 US FRESENIUS SE & CO KGAA DE0005785604 DE BIOCRYST PHARMACEUTICALS INC US09058V1035 US GENMAB A/S DK0010272202 DK BIODELIVERY SCIENCES INTL US09060J1060 US GENTIUM-SRL US37250B1044 IT BIOGEN INC US09062X1037 US GENVEC INC US37246C4069 US	BASILEA PHARMACEUTICA-REG	CH0011432447			US31572Q8087	
BAYER AG-REG         DE000BAY0017         DE         FORTRESS BIOTECH INC         US34960Q1094         US           BELLEROPHON THERAPEUTICS INC         US0787711029         US         FRESENIUS SE & CO KGAA         DE0005785604         DE           BIOCRYST PHARMACEUTICALS INC         US09058V1035         US         GENMAB A/S         DK0010272202         DK           BIODELIVERY SCIENCES INTL         US09060J1060         US         GENTIUM-SRL         US37250B1044         IT           BIOGEN INC         US09062X1037         US         GENVEC INC         US37246C4069         US	BAXALTA INC					
BELLEROPHON THERAPEUTICS INC US0787711029 US FRESENIUS SE & CO KGAA DE0005785604 DE BIOCRYST PHARMACEUTICALS INC US09058V1035 US GENMAB A/S DK0010272202 DK BIODELIVERY SCIENCES INTL US09060J1060 US GENTIUM-SRL US37250B1044 IT BIOGEN INC US09062X1037 US GENVEC INC US37246C4069 US	BAXTER INTERNATIONAL INC					
BIOCRYST PHARMACEUTICALS INC         US09058V1035         US         GENMAB A/S         DK0010272202         DK           BIODELIVERY SCIENCES INTL         US09060J1060         US         GENTIUM-SRL         US37250B1044         IT           BIOGEN INC         US09062X1037         US         GENVEC INC         US37246C4069         US	BAYER AG-REG					
BIODELIVERY SCIENCES INTL US09060J1060 US GENTIUM-SRL US37250B1044 IT BIOGEN INC US09062X1037 US GENVEC INC US37246C4069 US	BELLEROPHON THERAPEUTICS INC					
BIOGEN INC US09062X1037 US GENVEC INC US37246C4069 US						
	DIOGEN INC	USU9002X103/	US	GENVEC INC	USS1240U4U09	19

19

GERON CORP						
GLIEAD SCIENCES INC.   USSIGNED	GERON CORP	US3741631036	US	NOVO NORDISK A/S-B	DK0060534915	DK
GLANDSMITHER, INP. PLC   GB0005827887   US   US300001022   US   US3000001022   US   US3000000000000000000000000000000000000						
GLYCOMIMETICS INC   USB800001022   US   OMEROS CORP   USB821451029   USB   OMEROS CORP   USB821451029   USB80001072   CAB822101077   CAB822101077   CAB82101077   CAB8210107   CAB8210107   CAB82101077   CAB8210107						
GREEN CROSS MEDICAL SCIENCE  RES0171986987 ES  GORTOLIS SA  GTX INC  GYPHARMACEUTICALS PLC  GROSSISH687 GS  GONCOMOPHARMACEUTICAL SINC  US8623701001  US ONCOMOPHARMACEUTICAL SINC  US8633701001  US ORIGIN CYJ-CLASS B  FIGURO 11-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1						
GRIFIOLS SA  ESDIT 1998/087 ES  ONCOMED PHARMACEUTICALS INC  GW PHARMACEUTICALS INC  MININE PHARMACEUTICALS INC  INSPECT INC  INSP		US38000Q1022	US		US6821431029	
GTX INC WPHARMACEUTICALS PIC B0000304-46867 WPHARMACEUTICALS INC US94003711005 US ON/OPHARMACEUTICALS INC US94003711005 US OPHARMACEUTICALS INC US9400371006 US OPHARMACEUTICALS INC US940037100	GREEN CROSS MEDICAL SCIENCE	KR7142280007	KR	ONCOLYTICS BIOTECH INC	CA6823101077	CA
GW PHARMACEUTICALS PLC	GRIFOLS SA	ES0171996087	ES	ONCOMED PHARMACEUTICALS INC	US68234X1028	US
GW PHARMACEUTICALS PLC	GTX INC	US40052B2079	US	ONCONOVA THERAPEUTICS INC	US68232V3069	US
HALOZYME THERAPELITICS INC						
HORIZON PHARMA PLC						
HOSPIRA.INC						
HONIZON THERAPEUTICS LIC   US44915N1019   US   ORION OYJ-CLASS B   F10009014377   F1   INMUNICE BISIO CORP   US452521105   US   US452522105   US   US452522105   US   US452522016   US   US452522016   US   US45252016   US   US4525200   US   PHARMACULCS INC   US4525203   US   US4525200   US4525200   US   US452						
MMUNE DESIGN CORP						
IMMUNOCEN INC	HORIZON THERAPEUTICS LLC	US44915N1019	US	ORION OYJ-CLASS B	FI0009014377	FI
IMMUNOCELLULAR THERAPEUTICS   US4525362046   US   PACIFIA PHARMACITICALS INC   US685271005   US   US452971080   US   PACIFIARM INC   US682971080   US   PRINCIPAL PHARMACITICALS INC   US77187311035   US   PRINCIPAL PHARMACITICALS INC   US4592650300   US   PRINCIPAL PHARMACITICALS INC   US459265030   US   PRINCIPAL PHARMACITICALS INC   US459265030   US   PRINCIPAL PHARMACITICALS INC   US72940781030   US   PRINCIPAL PHARMACITICALS INC   US72940781030   US   US4592522104   US   PRINCIPAL PHARMACITICALS INC   US72940781030   US   US4592522104   US   PRINCIPAL PHARMACITICALS INC   US7394371030   US   US4592522104   US   PRINCIPAL PHARMACITICALS INC   US7391791030   US   US4592522104   US   PRINCIPAL PHARMACITICALS INC   US7391791030   US   US459252104   US   PRINCIPAL PHARMACITICALS INC   US7391791030   US   US459252104   US   PRINCIPAL PHARMACITICALS INC   US7391791030   US   US4592541037   US   PRINCIPAL PHARMACITICALS INC   US7391791030   US   PRINCIPAL PHARMACITICALS INC   US7391711030   US   PRINCIPAL PHARMACITICALS INC   US7391791030   US7391711030   US   PRINCIPAL PHARMACITICALS INC   US7391791030   US   PRINCIPAL PHARMACITICALS INC   US7391791030   US   PRINCIPAL PHARMACITICAL COLOT   US440851048   US4408	IMMUNE DESIGN CORP	US45252L1035	US	OSIRIS THERAPEUTICS INC	US68827R1086	US
IMMUNOCELLULAR THERAPEUTICS   US4525362046   US   PACIFICA PHARMACEUTICALS INC   US695271005   US   US452971090   US   POL RIOPHARM INC   US695271005   US   POL RIOPHARM INC   US695271005   US   POL RIOPHARM INC   US695271005   US   POL RIOPHARM INC   US7952971030   US   PERRICO CO PLC   E10086H11M598   US   POL RIOPHARM INC   US795331060   US   PERRICO CO PLC   US771033105   US   US4528710107   US   PHARMACHARMACEUTICALS INC   US795331060   US   PHARMACHARMACEUTICALS INC   US4596953029   US   PHARMACHARMACEUTICALS INC   US795969108   US   US4696953029   US   PHARMACHARMACEUTICALS INC   US79596108   US   PROPERTION INC   US79596109   US   US79596109   US795961	IMMUNE PHARMACEUTICALS INC	US45254C2008	US	OTSUKA HOLDINGS CO LTD	JP3188220002	JP
IMMUNOGEN INC						
IMMUNOMEDICS INC						
IMPAX LABORATORIES INC						
INCYTE CORP						
INDIVIDE PLC   GROOBENSEANAS   GB	IMPAX LABORATORIES INC	US45256B1017		-	US7170811035	
INFINITY PHARMACEUTICALS INC	INCYTE CORP	US45337C1027	US	PHARMACYCLICS INC	US7169331060	US
INSPER THERAPEUTICS INC	INDIVIOR PLC	GB00BRS65X63	GB	PHARMA MAR SA	ES0169501030	ES
INSPER THERAPEUTICS INC	INFINITY PHARMACEUTICALS INC	US45665G3039	US	PHARMAXIS LTD	AU000000PXS5	AU
INSPER THERAPEUTICS INC						
INTERCEPT PHARMACEUTICALS IN						
INTEREMUR INC						
INTERMUNE INC						
IONIS PHARMACEUTICALS INC	INTERCEPT PHARMACEUTICALS IN	US45845P1084	US	PORTOLA PHARMACEUTICALS INC	US7370101088	
PSEN	INTERMUNE INC	US45884X1037	US	PROGENICS PHARMACEUTICALS	US7431871067	US
JAZZ PHARMACEUTICALS PLC	IONIS PHARMACEUTICALS INC	US4622221004	US	PROQR THERAPEUTICS NV	NL0010872495	NL
JAZZ PHARMACEUTICALS PLC	IPSEN	FR0010259150	FR	PROSENSA HOLDING NV	NL0010524443	NL
JOHNSON & JOHNSON   U5478161046   US	JAZZ PHARMACELITICALS PLC	IE00B4O57N47				
JUND THERAPEUTICS INC						
HUMANIGEN INC						
KARNOPHARM THERAPEUTICS INC   LIS4857611060 US   PTC THERAPEUTICS INC   US88361,2006 US   KISSEI PHARMACEUTICAL CO LTD   JP3246600001						
KARYOPHARM THERAPEUTICS INC   US485761/1060   US   PTC THERAPEUTICS INC   US48586,2006   US   KISSEI PHARMACEUTICAL CO LTD   JP3246900001   JP   HORIZON PHARMACEUTICAL LLC   US75838271068   US   KITE PHARMA INC   US4903L1098   US   RECKITT BENCKISER GROUP PLC   GB00B24CGK77   GB   KVORIN HOLDINGS INC   US5012771097   US   RECORDATI SPA   RECORDATI SPA   TI0003828271   IT   TI000382						
INSSEI PHARMACEUTICAL CO LTD	KAMADA LTD	IL0010941198	IL	PSIVIDA CORP	US74440J1016	US
KITE PHARMA INC         US48903-11098         US         RECKITT BENCKISER GROUP PLC         GB00B24CGK77         GB           KURA ONCOLOGY INC         US50127T1097         US         RECORDATI SPA         IT00303828271         IT           KYORIN HOLDINGS INC         JP3247090008         JP         REGURSON PHARMACEUTICALS         US75866F1075         US           LEXICON PHARMACEUTICALS INC         US5288723027         US         REGULUS THERAPEUTICS INC         US7612991064         US           LEXICON PHARMACEUTICALS INC         US52288723027         US         RIGGL PHARMACEUTICALS INC         US766596034         US           LOXO ONCOLOGY INC         US4622801007         US         SAGENT PHARMACEUTICALS INC         US7666596034         US           LOXO ONCOLOGY INC         US4622801007         US         SAGENT PHARMACEUTICALS INC         US76865901034         US           MACROGENICS INC         US5488621013         US         SANDGI         FRRO000120578         FR           MALINICKROOT PLC         IE00BBGT3753         US         SANTERD PHARMACEUTICAL COLT         US8028713940         US           MEDICIS PHARMACEUTICAL CORP         US5766781097         US         SANTERD PHARMACEUTICAL COLT         JP3336000009         US           MERCIK K GAA         US5869372982025 </td <td>KARYOPHARM THERAPEUTICS INC</td> <td>US48576U1060</td> <td>US</td> <td>PTC THERAPEUTICS INC</td> <td>US69366J2006</td> <td>US</td>	KARYOPHARM THERAPEUTICS INC	US48576U1060	US	PTC THERAPEUTICS INC	US69366J2006	US
KITE PHARMA INC         US48903-11098         US         RECKITT BENCKISER GROUP PLC         GB00B24CGK77         GB           KURA ONCOLOGY INC         US50127T1097         US         RECORDATI SPA         IT00303828271         IT           KYORIN HOLDINGS INC         JP3247090008         JP         REGURSON PHARMACEUTICALS         US75866F1075         US           LEXICON PHARMACEUTICALS INC         US5288723027         US         REGULUS THERAPEUTICS INC         US7612991064         US           LEXICON PHARMACEUTICALS INC         US52288723027         US         RIGGL PHARMACEUTICALS INC         US766596034         US           LOXO ONCOLOGY INC         US4622801007         US         SAGENT PHARMACEUTICALS INC         US7666596034         US           LOXO ONCOLOGY INC         US4622801007         US         SAGENT PHARMACEUTICALS INC         US76865901034         US           MACROGENICS INC         US5488621013         US         SANDGI         FRRO000120578         FR           MALINICKROOT PLC         IE00BBGT3753         US         SANTERD PHARMACEUTICAL COLT         US8028713940         US           MEDICIS PHARMACEUTICAL CORP         US5766781097         US         SANTERD PHARMACEUTICAL COLT         JP3336000009         US           MERCIK K GAA         US5869372982025 </td <td>KISSEI PHARMACEUTICAL CO LTD</td> <td>JP3240600001</td> <td>JP</td> <td>HORIZON PHARMACEUTICAL LLC</td> <td>US75382F1066</td> <td>US</td>	KISSEI PHARMACEUTICAL CO LTD	JP3240600001	JP	HORIZON PHARMACEUTICAL LLC	US75382F1066	US
NURA ONCOLOGY INC						
VYORIN HOLDINGS INC						-
AVYOWA HAKKO KIRIN CO LTD						
LABORATORIOS FARMACEUTICALS INC   LEXICON PHARMACEUTICALS INC   US\$288723027   US   RIGEL PHARMACEUTICALS INC   US\$65596034   US   RIGEL PHARMACEUTICALS INC   US\$65596034   US   ROCHE HOLDING AG-GENUSSCHEIN   CH0012032048   CH   IOVANCE BIOTHERAPEUTICS INC   US\$622601007   US   SAGENT PHARMACEUTICALS INC   US7866921031   US   US4622661037   US   SAGENT PHARMACEUTICALS INC   US7866921031   US   US4622661037   US   SAGENT PHARMACEUTICALS INC   US7866921031   US   US4622661031   US   SALIX PHARMACEUTICALS INC   US7866921031   US   US4622661031   US   SALIX PHARMACEUTICALS INC   US806771062   US   MACROGENICS INC   US5560991094   US   SANOFI   FR0000120578   FR   MALLINCKRODT PLC   IE00BBGT3753   US   SANTARUS INC   US806711062   US   SANTARUS INC   US8051111016   US   SANTEN PHARMACEUTICAL CO LTD   JP3336000009   JP   MATEON THERAPEUTICS INC   US8567671037   US   SANTHERA PHARMACEUTICAL CO LTD   JP3336000009   JP   MATEON THERAPEUTICS INC   US8057671004   US   SANTHERA PHARMACEUTICALS INC   US803671004   US   US8036771004   US   US803771007   USS036771004   US   US8036771004   US   US8036771004   US   US8036771007   USS036771007   USS03771007   USS036771007   USS036771007						
LEXICON PHARMACEUTICALS INC         US5288723027         US         RIGEL PHARMACEUTICALS INC         US7665596034         US           LIGAND PHARMACEUTICALS INC IOVANCE BIOTHERAPEUTICS INC         US4622601007         US         SAGENT PHARMACEUTICALS INC         US7686921031         US           LOXO ONCOLOGY INC         US5488621013         US         SALIX PHARMACEUTICALS LTD         US7954351067         US           H LUNDBECK AYS         DK0010287234         WK         SANGAMO THERAPEUTICS INC         US806771062         US           MACROGENICS INC         US5560991094         US         SANTARUS INC         US8028173040         US           SAVARA INC         US80511111016         US         SANTARUS INC         US8028173040         US           MEDA AB-A SHS         SE0000221723         SE         SARTEN PHARMACEUTICAL COLTD         JP3336000099         US           MEDIGIS PHARMACEUTICAL CORP         US58648603095         US         SAVIENT PHARMACEUTICALS INC         US808671004         US           MERICK & CO. INC.         US582788205         US         SEATITLE GENETICS INC         US808671004         US           MERCK & CO. INC.         US58933Y1055         US         SHINCE PLC         JB00062679057         US           MERRIMACK PHARMACEUTICAL CO         MS90322820						
LIGAND PHARMACEUTICALS         US\$3220K5048         US         ROCHE HOLDING AG-GENUSSCHEIN         CH0012032048         CH           IOVANCE BIOTHERAPEUTICS INC         US4622601007         US         SAGENT PHARMACEUTICALS INC         US7866921031         US           LUNDBECK A'S         DK0010287234         DK         SANGAMO THERAPEUTICS INC         US8006771062         US           MACROGENICS INC         US5569991904         US         SANOFI         FR0000120578         FR           MALLINCKRODT PLC         IE00BBGT3753         US         SANTARUS INC         US8028173040         US           SAVARA INC         US57667K1097         US         SANTHEN PHARMACEUTICAL COLTD         JP3336000009         JP           MEDIA AB-A SHS         SE0000221723         SE         SAREPTA THERAPEUTICS INC         US8036071004         US           MEDIGEN PHARMACEUTICAL CORP         US586983911055         US         SAVIENT PHARMACEUTICALS INC         US8036871004         US           MERCK & CO. INC.         US589393711055         US         SAVIENT PHARMACEUTICALS INC         US80662K1043         US           MERCK & CO. INC.         US59006659905         DE         SHIRC PLC         JE0082CKY057         US           MERRIMACK PHARMACEUTICALS IN         US5093371055         US <td>LABORATORIOS FARMACEUTICOS R</td> <td></td> <td>ES</td> <td></td> <td>US7612991064</td> <td></td>	LABORATORIOS FARMACEUTICOS R		ES		US7612991064	
DOVANCE BIOTHERAPEUTICS INC	LEXICON PHARMACEUTICALS INC	US5288723027	US	RIGEL PHARMACEUTICALS INC	US7665596034	US
LOXO ONCOLOGY INC	LIGAND PHARMACEUTICALS	US53220K5048	US	ROCHE HOLDING AG-GENUSSCHEIN	CH0012032048	CH
LOXO ONCOLOGY INC	IOVANCE BIOTHERAPEUTICS INC	US4622601007	US	SAGENT PHARMACEUTICALS INC	US7866921031	US
HUNDBECK A/S   MACROGENICS INC						
MACROGENICS INC         US5560991094         US         SANOFI         FR0000120578         FR           MALLINCKRODT PLC         IE00BBGT37533         US         SANTARUS INC         US8028173040         US           SAVARA INC         US8051111016         US SANTEN PHARMACEUTICAL CO LTD         JP3336000009         JP           MEDA AB-A SHS         US57667K1097         US         SANTHERA PHARMACEUTICALS REG         CH0027148649         CH           MEDIGIS PHARMACEUTICAL CORP         US5846903095         US         SAVIENT PHARMACEUTICALS INC         US8036071004         US           MEDIGIS PHARMACEUTICAL CORP         US5846903095         US         SAVIENT PHARMACEUTICALS INC         US80361701004         US           MEDIGIS PHARMA INC         US5527982025         US         SECICLONE PHARMACEUTICALS INC         US80862K1043         US           MERCK K GAA         DE0006599905         US         SEATTLE GENETICS INC         US8269171067         US           MESOBLAST LTD         AU000000MSB8         AU         SIGA TECHNOLOGIES INC         US8269171067         US           MITSUBISHI TANABE PHARMA         JP3469000008         JP         SPECTRUM PHARMACEUTICALS INC         US84652J1034         US           MOCHIDA PHARMACEUTICALS INC         US60867771007         US						
MALLINCKRODT PLC         IE00BBGT3753         US         SANTARUS INC         US80511110106         US         SANTEN PHARMACEUTICAL CO LTD         JP333600009         JP           MATEON THERAPEUTICS INC         US57667K1097         US         SANTHERA PHARMACEUTICALS-REG         CH0027148649         CH           MEDIA AB-A SHS         SE0000221723         SE         SAREPTA THERAPEUTICS INC         US8036071004         US           MEDICIS PHARMACEUTICAL CORP         US5846903095         US         SAVIENT PHARMACEUTICALS INC         US80651701004         US           MEDIGENE AG         DE000A133W00         DE         SCICLONE PHARMACEUTICALS INC         US80868214043         US           MEIP PHARMA INC         US55279B2025         US         SEATTLE GENETICS INC         US8125781026         US           MERCK & CO. INC.         US58933Y1055         US         SHICNOGIS & CO LTD         JP3347200002         JP           MERCK K GGA         DE0006599905         DE         SHIRE PLC         US8269171067         US           MERRIMACK PHARMACEUTICALS IN         US6046871051         US         SIGA TECHNOLOGIES INC         US8269171067         US           MERSUS SHIT TANABE PHARMA         JP346900008         AU         SMITH & NEPHEW PLC         GB0009223206         GB <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td></t<>						
SAVARA INC						
MATEON THERAPEUTICS INC         US\$7667K1097         US         SANTHERA PHARMACEUTICALS-REG         CH0027148649         CH           MEDICIS PHARMACEUTICAL CORP         US\$846903095         US         SAREPTA THERAPEUTICS INC         US8031701004         US           MEDIGS PHARMACEUTICAL CORP         US\$844903095         US         SAVIENT PHARMACEUTICALS INC         US8031701004         US           MEDIGENE AG         DE000A1X3W00         DE         SCICLONE PHARMACEUTICALS INC         US8026871026         US           MEI PHARMA INC         US\$527982025         US         SEATTLE GENETICS INC         US8125781026         US           MERCK & CO. INC.         US\$6933Y1055         US         SHINE PLC         JP3347200002         JP           MERCK K GGA         DE0006599905         DE         SHIRE PLC         JE00B2QKY057         US           MESOBLAST LTD         AU000000MSB8         AU         SMITH & NEPHEW PLC         G8009223206         GB           MIRATI THERAPEUTICS INC         US6046871051         US         SPARK THERAPEUTICS INC         US84652J1034         US           MICHIDA PHARMACEUTICAL CO         JP3922800002         JP         STADA ARZNEIMITTEL AG         DE0007251803         DE           MOMENTA PHARMACEUTICAL CO         JP3922800002         JP <td>MALLINCKRODT PLC</td> <td>IE00BBGT3753</td> <td></td> <td></td> <td>US8028173040</td> <td></td>	MALLINCKRODT PLC	IE00BBGT3753			US8028173040	
MEDA AB-A SHS         SE0000221723         SE         SAREPTA THERAPEUTICS INC         US8036071004         US           MEDICIS PHARMACEUTICAL CORP         US5846903095         US         SAVIENT PHARMACEUTICALS INC         US8051701004         US           MEI PHARMA INC         US55279B2025         US         SEATTLE GENETICS INC         US8125781026         US           MERCK & CO. INC.         US58279B2025         US         SHINCOGI & CO LTD         JP3347200002         JP           MERCK & CO. INC.         US5893391055         US         SHIONOGI & CO LTD         JP3347200002         JP           MERCK KGAA         DE0006599905         DE         SHIRE PLC         JE00B2QKY057         US           MERSOBLAST LTD         AU000000MSB8         AU         SIGA TECHNOLOGIES INC         US8269171067         US           MITSUBISHI TANABE PHARMA         JP3469000008         JP         SPECTRUM PHARMACEUTICALS INC         US84652J1034         US           MOCHIDA PHARMACEUTICAL CO         JP39222800002         JP         STADA ARZNEIMITTEL AG         DE0007251803         DE           MYLAN NV         NL0011031208         US         SUMITOMO DAINIPPON PHARMACEUTICALS INC         US865649091068         US           NEKTAR THERAPEUTICS         US6402681083         US	SAVARA INC	US8051111016	US	SANTEN PHARMACEUTICAL CO LTD	JP3336000009	JP
MEDICIS PHARMACEUTICAL CORP         US5846903095         US         SAVIENT PHARMACEUTICALS INC         US80517Q1004         US           MEDIGENE AG         DE000A1X3W00         DE         SCICLONE PHARMACEUTICALS INC         US80862K1043         US           MEI PHARMA INC         US55279B2025         US         SEATTLE GENETICS INC         US8125781026         US           MERCK & CO. INC.         US58933Y1055         US         SHIONOGI & CO LTD         JP3347200002         JP           MERCK KGAA         DE0006599905         DE         SHIRE PLC         JE00820KY057         US           MERRIMACK PHARMACEUTICALS IN         US5903282094         US         SIGA TECHNOLOGIES INC         US8269171067         US           MIRATI THERAPEUTICS INC         US6046871051         US         SPARK THERAPEUTICS INC         US84652J1034         US           MISUBISHI TANABE PHARMA         JP3469000008         JP         STECTRUM PHARMACEUTICALS INC         US84652J1034         US           MOCHIDA PHARMACEUTICAL CO         JP3922800002         JP         STEADYMED LTD         IL0011348997         IL           MOPHOSYS AG         DE0006632003         DE         STEMLINE THERAPEUTICS INC         US8685861071         US           MYLAN NV         NLOTAL SERVARIA         US	MATEON THERAPEUTICS INC	US57667K1097	US	SANTHERA PHARMACEUTICALS-REG	CH0027148649	CH
MEDICIS PHARMACEUTICAL CORP         US5846903095         US         SAVIENT PHARMACEUTICALS INC         US80517Q1004         US           MEDIGENE AG         DE000A1X3W00         DE         SCICLONE PHARMACEUTICALS INC         US80862K1043         US           MEI PHARMA INC         US55279B2025         US         SEATTLE GENETICS INC         US8125781026         US           MERCK & CO. INC.         US58933Y1055         US         SHIONOGI & CO LTD         JP3347200002         JP           MERCK KGAA         DE0006599905         DE         SHIRE PLC         JE00820KY057         US           MERRIMACK PHARMACEUTICALS IN         US5903282094         US         SIGA TECHNOLOGIES INC         US8269171067         US           MIRATI THERAPEUTICS INC         US6046871051         US         SPARK THERAPEUTICS INC         US84652J1034         US           MISUBISHI TANABE PHARMA         JP3469000008         JP         STECTRUM PHARMACEUTICALS INC         US84652J1034         US           MOCHIDA PHARMACEUTICAL CO         JP3922800002         JP         STEADYMED LTD         IL0011348997         IL           MOPHOSYS AG         DE0006632003         DE         STEMLINE THERAPEUTICS INC         US8685861071         US           MYLAN NV         NLOTAL SERVARIA         US	MEDA AB-A SHS	SE0000221723	SE	SAREPTA THERAPEUTICS INC	US8036071004	US
MEDIGENE AG         DE000A1X3W00         DE         SCICLONE PHARMACEUTICALS INC         US80862K1043         US           MEI PHARMA INC         US55279B2025         US         SEATTLE GENETICS INC         US4125781026         US           MERCK & CO. INC.         US58933Y1055         US         SHONOGI & CO LTD         JP3347200002         JP           MERCK & GAA         DE0006599905         DE         SHIRE PLC         JE00B20KY057         US           MERRIMACK PHARMACEUTICALS IN         US5903282094         US         SIGA TECHNOLOGIES INC         US8269171067         US           MESOBLAST LTD         AU0000000MSB8         AU         SMITH & NEPHEW PLC         GB0009223206         GB           MIRATI THERAPEUTICS INC         US60468T1051         US         SPARK THERAPEUTICS INC         US84652J1034         US           MITSUBISHI TANABE PHARMA         JP3469000008         JP         SPECTRUM PHARMACEUTICALS INC         US84763A1088         US           MOCHIDA PHARMACEUTICAL CO         JP3922800002         JP         STADA ARZNEIMITTEL AG         DE0007251803         DE           MORPHOSYS AG         DE0006632003         DE         STEMLINE THERAPEUTICS INC         US88658C1071         US           MYLAN NV         NLO011031208         US         SUCAMPO PHA				SAVIENT PHARMACELITICALS INC.		
MEI PHARMA INC         US55279B2025         US         SEATTLE GENETICS INC         US8125781026         US           MERCK & CO. INC.         US58933Y1055         US         SHIONOGI & CO LTD         JP3347200002         JP           MERCK KGAA         DE0006599905         DE         SHIRE PLC         JE00B2QKY057         US           MERRIMACK PHARMACEUTICALS IN         US5903282094         US         SIGA TECHNOLOGIES INC         US8269171067         US           MESOBLAST LTD         AU000000MSB8         AU         SMITH & NEPHEW PLC         GB0009223206         GB           MIRATI THERAPEUTICS INC         US6046871051         US         SPARK THERAPEUTICS INC         US84652J1034         US           MITSUBISHI TANABE PHARMA         JP3469000008         JP         SPECTRUM PHARMACEUTICALS INC         US84763A1088         US           MOCHIDA PHARMACEUTICAL CO         JP3922800002         JP         STADA ARZNEIMITTEL AG         DE0007251803         DE           MORPHOSYS AG         DE0006632003         DE         STEMLINE THERAPEUTICS INC         US86489091068         US           MYLAN NV         NLO011031208         US         SUCAMPO PHARMACEUTICALS-CL A         US8649091068         US           NESTLE SA-REG         CH0038863350         CH         SUNESIS P						
MERCK & CO. INC.         US58933Y1055         US         SHIONOGI & CO LTD         JP3347200002         JP           MERCK KGAA         DE0006599905         DE         SHIRE PLC         JE00B2QKY057         US           MERRIMACK PHARMACEUTICALS IN         US5903282094         US         SIGA TECHNOLOGIES INC         US8269171067         US           MESOBLAST LTD         AU000000MSB8         AU         SMITH & NEPHEW PLC         GB0009223206         GB           MIRATI THERAPEUTICS INC         US60468T1051         US         SPARK THERAPEUTICS INC         US84652J1034         US           MITSUBISHI TANABE PHARMA         JP3469000008         JP         SPECTRUM PHARMACEUTICALS INC         US84763A1088         US           MOCHIDA PHARMACEUTICAL CO         JP3922800002         JP         STADA ARZNEIMITTEL AG         DE0007251803         DE           MORPHOSYS AG         DE0006632003         DE         STEMLINE THERAPEUTICS INC         US85858C1071         US           MYLAN NV         NL0011031208         US         SUCAMPO PHARMACEUTICALS INC         US8649091068         US           NESTLE SA-REG         CH0038863350         CH         SUNESIS PHARMACEUTICALS INC         US8673287004         US           NEURALSTEM INC         US64125784011         US         SYM						
MERCK KGAA         DE0006599905         DE         SHIRE PLC         JE00B2QKY057         US           MERRIMACK PHARMACEUTICALS IN         US5903282094         US         SIGA TECHNOLOGIES INC         US8269171067         US           MESOBLAST LTD         AU000000MSB8         AU         SMITH & NEPHEW PLC         GB0009223206         GB           MIRATI THERAPEUTICS INC         US60468T1051         US         SPARK THERAPEUTICS INC         US84652J1034         US           MITSUBISHI TANABE PHARMA         JP3469000008         JP         SPECTRUM PHARMACEUTICALS INC         US84652J1034         US           MOCHIDA PHARMACEUTICAL CO         JP3922800002         JP         STADA ARZNEIMITTEL AG         DE0007251803         DE           MOMENTA PHARMACEUTICALS INC         US60877T1007         US         STEADYMED LTD         IL0011348997         IL           MOPHOSYS AG         DE0006632003         DE         STEMLINE THERAPEUTICS INC         US8649091068         US           NEKTAR THERAPEUTICS         US6402681083         US         SUCAMPO PHARMACEUTICALS-CL A         US8649091068         US           NESTLE SA-REG         CH0038863350         CH         SUNESIS PHARMACEUTICALS INC         US8673287004         US           NEURALSTEM INC         US6412521014         US <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>						
MERRIMACK PHARMACEUTICALS IN         US5903282094         US         SIGA TECHNOLOGIES INC         US8269171067         US           MESOBLAST LTD         AU000000MSB8         AU         SMITH & NEPHEW PLC         GB0009223206         GB           MIRATI THERAPEUTICS INC         US60468T1051         US         SPARK THERAPEUTICS INC         US84652J1034         US           MITSUBISHI TANABE PHARMA         JP3469000008         JP         SPECTRUM PHARMACEUTICALS INC         US84763A1088         US           MOCHIDA PHARMACEUTICAL CO         JP3922800002         JP         STADA ARZNEIMITTEL AG         DE0007251803         DE           MOMENTA PHARMACEUTICALS INC         US60877T1007         US         STEADYMED LTD         IL0011348997         IL           MORPHOSYS AG         DE0006632003         DE         STEMLINE THERAPEUTICS INC         US85858C1071         US           MYLAN NV         NL0011031208         US         SUCAMPO PHARMACEUTICALS-CL A         US8649091068         US           NEKTAR THERAPEUTICS         US6402681083         US         SUMITOMO DAINIPPON PHARMA CO         JP3495000006         JP           NESTLE SA-REG         CH0038863350         CH         SUNESIS PHARMACEUTICALS INC         US8673287004         US           NEURALSTEM INC         US64127R4011						
MESOBLAST LTD         AU000000MSB8         AU         SMITH & NEPHEW PLC         GB0009223206         GB           MIRATI THERAPEUTICS INC         US60468T1051         US         SPARK THERAPEUTICS INC         US84652J1034         US           MIRATI THERAPEUTICS INC         US60468T1051         US         SPARK THERAPEUTICS INC         US84763A1088         US           MOCHIDA PHARMACEUTICAL CO         JP3922800002         JP         STADA ARZNEIMITTEL AG         DE0007251803         DE           MOMENTA PHARMACEUTICALS INC         US606877T1007         US         STEADYMED LTD         IL0011348997         IL           MORPHOSYS AG         DE0006632003         DE         STEMLINE THERAPEUTICS INC         US85858C1071         US           MYLAN NV         NL0011031208         US         SUCAMPO PHARMACEUTICALS-CL A         US8649091068         US           NEKTAR THERAPEUTICS         US6402681083         US         SUMITOMO DAINIPPON PHARMA CO         JP3495000006         JP           NESTLE SA-REG         CH0038863350         CH         SUNESIS PHARMACEUTICALS INC         US8673287004         US           NEUROGESX INC         US6412784011         US         SYMBIO PHARMACEUTICALS ITD         JP3383050006         JP           NEWLINK GENETICS CORP         US6515111077         <						
MIRATI THERAPEUTICS INC         US60468T1051         US         SPARK THERAPEUTICS INC         US84652J1034         US           MITSUBISHI TANABE PHARMA         JP3469000008         JP         SPECTRUM PHARMACEUTICALS INC         US84763A1088         US           MOCHIDA PHARMACEUTICAL CO         JP3922800002         JP         STADA ARZNEIMITTEL AG         DE0007251803         DE           MOMENTA PHARMACEUTICALS INC         US60877T1007         US         STEADYMED LTD         IL0011348997         IL           MORPHOSYS AG         DE0006632003         DE         STEMLINE THERAPEUTICS INC         US85858C1071         US           MYLAN NV         NL0011031208         US         SUCAMPO PHARMACEUTICALS-CL A         US8649091068         US           NESTLE SA-REG         US6402681083         US         SUMITOMO DAINIPPON PHARMA CO         JP3495000006         JP           NESTLE SA-REG         CH0038863350         CH         SUNESIS PHARMACEUTICALS INC         US8673287004         US           NEUROGESX INC         US64127R4011         US         SWEDISH ORPHAN BIOVITRUM AB         SE0000872095         SE           NEWLINK GENETICS CORP         US6515111077         US         SYNAGEVA BIOPHARMACEUTICALS LTD         JP3383050006         JP           NICHI-IKO PHARMACEUTICAL CO <td< td=""><td>MERRIMACK PHARMACEUTICALS IN</td><td>US5903282094</td><td>US</td><td>SIGA TECHNOLOGIES INC</td><td>US8269171067</td><td>US</td></td<>	MERRIMACK PHARMACEUTICALS IN	US5903282094	US	SIGA TECHNOLOGIES INC	US8269171067	US
MITSUBISHI TANABE PHARMA         JP3469000008         JP         SPECTRUM PHARMACEUTICALS INC         US84763A1088         US           MOCHIDA PHARMACEUTICAL CO         JP3922800002         JP         STADA ARZNEIMITTEL AG         DE0007251803         DE           MOMENTA PHARMACEUTICALS INC         US60877T1007         US         STEADYMED LTD         IL0011348997         IL           MORPHOSYS AG         DE0006632003         DE         STEMLINE THERAPEUTICS INC         US85858C1071         US           MYLAN NV         NL0011031208         US         SUCAMPO PHARMACEUTICALS-CL A         US8649091068         US           NEKTAR THERAPEUTICS         US6402681083         US         SUMITOMO DAINIPPON PHARMA CO         JP3495000006         JP           NESTLE SA-REG         CH0038863350         CH         SUNESIS PHARMACEUTICALS INC         US8673287004         US           NEUROGESX INC         US64127R4011         US         SWEDISH ORPHAN BIOVITRUM AB         SE0000872095         SE           NEWLINK GENETICS CORP         US6515111077         US         SYNAGEVA BIOPHARMA CORP         US87159A1034         US           NICHI-IKO PHARMACEUTICAL CO         JP3687200000         JP         TAKEDA PHARMACEUTICAL CO LTD         JP3463000004         JP           NIPPON KAYAKU CO LTD <t< td=""><td>MESOBLAST LTD</td><td>AU000000MSB8</td><td>AU</td><td>SMITH &amp; NEPHEW PLC</td><td>GB0009223206</td><td>GB</td></t<>	MESOBLAST LTD	AU000000MSB8	AU	SMITH & NEPHEW PLC	GB0009223206	GB
MITSUBISHI TANABE PHARMA         JP3469000008         JP         SPECTRUM PHARMACEUTICALS INC         US84763A1088         US           MOCHIDA PHARMACEUTICAL CO         JP3922800002         JP         STADA ARZNEIMITTEL AG         DE0007251803         DE           MOMENTA PHARMACEUTICALS INC         US60877T1007         US         STEADYMED LTD         IL0011348997         IL           MORPHOSYS AG         DE0006632003         DE         STEMLINE THERAPEUTICS INC         US85858C1071         US           MYLAN NV         NL0011031208         US         SUCAMPO PHARMACEUTICALS-CL A         US8649091068         US           NEKTAR THERAPEUTICS         US6402681083         US         SUMITOMO DAINIPPON PHARMA CO         JP3495000006         JP           NESTLE SA-REG         CH0038863350         CH         SUNESIS PHARMACEUTICALS INC         US8673287004         US           NEUROGESX INC         US64127R4011         US         SWEDISH ORPHAN BIOVITRUM AB         SE0000872095         SE           NEWLINK GENETICS CORP         US6515111077         US         SYNAGEVA BIOPHARMA CORP         US87159A1034         US           NICH-IKO PHARMACEUTICAL CO         JP3687200000         JP         TAKEDA PHARMACEUTICAL CO LTD         JP3463000004         JP           NIPPON KAYAKU CO LTD <td< td=""><td>MIRATI THERAPEUTICS INC</td><td>US60468T1051</td><td>US</td><td>SPARK THERAPEUTICS INC</td><td>US84652J1034</td><td>US</td></td<>	MIRATI THERAPEUTICS INC	US60468T1051	US	SPARK THERAPEUTICS INC	US84652J1034	US
MOCHIDA PHARMACEUTICAL CO         JP3922800002         JP         STADA ARZNEIMITTEL AG         DE0007251803         DE           MOMENTA PHARMACEUTICALS INC         US60877T1007         US         STEADYMED LTD         IL0011348997         IL           MORPHOSYS AG         DE0006632003         DE         STEMLINE THERAPEUTICS INC         US85858C1071         US           MYLAN NV         NL0011031208         US         SUCAMPO PHARMACEUTICALS-CL A         US8649091068         US           NEKTAR THERAPEUTICS         US6402681083         US         SUMITOMO DAINIPPON PHARMA CO         JP3495000006         JP           NESTLE SA-REG         CH0038863350         CH         SUNESIS PHARMACEUTICALS INC         US8673287004         US           NEURALSTEM INC         US64127R4011         US         SWEDISH ORPHAN BIOVITRUM AB         SE0000872095         SE           NEUROGESX INC         US6412521014         US         SYMBIO PHARMACEUTICALS LTD         JP3383050006         JP           NEWLINK GENETICS CORP         US6515111077         US         SYNAGEVA BIOPHARMA CORP         US87159A1034         US           NIPPON KAYAKU CO LTD         JP3687200000         JP         TAKEDA PHARMACEUTICAL CO LTD         JP3544000007         JP           NIPPON SHINYAKU CO LTD         JP3717600005 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>						
MOMENTA PHARMACEUTICALS INC         US60877T1007         US         STEADYMED LTD         IL0011348997         IL           MORPHOSYS AG         DE0006632003         DE         STEMLINE THERAPEUTICS INC         US85858C1071         US           MYLAN NV         NL0011031208         US         SUCAMPO PHARMACEUTICALS-CL A         US8649091068         US           NEKTAR THERAPEUTICS         US6402681083         US         SUMITOMO DAINIPPON PHARMA CO         JP3495000006         JP           NESTLE SA-REG         CH0038863350         CH         SUNESIS PHARMACEUTICALS INC         US8673287004         US           NEUROGESX INC         US64127R4011         US         SWEDISH ORPHAN BIOVITRUM AB         SE0000872095         SE           NEUROGESX INC         US6412521014         US         SYMBIO PHARMACEUTICALS LTD         JP3383050006         JP           NEWLINK GENETICS CORP         US65151111077         US         SYNAGEVA BIOPHARMA CORP         US87159A1034         US           NICHI-IKO PHARMACEUTICAL CO         JP3687200000         JP         TAKEDA PHARMACEUTICAL CO LTD         JP3463000004         JP           NIPPON KAYAKU CO LTD         JP3694400007         JP         TEJIN LTD         JP3544000007         JP           NIPPON SHINYAKU CO LTD         JP3717600005						
MORPHOSYS AG         DE0006632003         DE         STEMLINE THERAPEUTICS INC         US85858C1071         US           MYLAN NV         NL0011031208         US         SUCAMPO PHARMACEUTICALS-CL A         US8649091068         US           NEKTAR THERAPEUTICS         US6402681083         US         SUMITOMO DAINIPPON PHARMA CO         JP3495000006         JP           NESTLE SA-REG         CH0038863350         CH         SUNESIS PHARMACEUTICALS INC         US8673287004         US           NEURALSTEM INC         US64127R4011         US         SWEDISH ORPHAN BIOVITRUM AB         SE0000872095         SE           NEUROGESX INC         US6412521014         US         SYMBIO PHARMACEUTICALS LTD         JP3383050006         JP           NEWLINK GENETICS CORP         US6515111077         US         SYNAGEVA BIOPHARMA CORP         US87159A1034         US           NICHI-IKO PHARMACEUTICAL CO         JP3687200000         JP         TAKEDA PHARMACEUTICAL CO LTD         JP3463000004         JP           NIPPON KAYAKU CO LTD         JP3694400007         JP         TEJIN LTD         JP3544000007         JP           NIPPON SHINYAKU CO LTD         JP3717600005         JP         TESARO INC         US8815691071         US           ALPINE IMMUNE SCIENCES INC         US66737P6007 <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td></td<>						
MYLAN NV         NL0011031208         US         SUCAMPO PHARMACEUTICALS-CL A         US8649091068         US           NEKTAR THERAPEUTICS         US6402681083         US         SUMITOMO DAINIPPON PHARMA CO         JP3495000006         JP           NESTLE SA-REG         CH0038863350         CH         SUNESIS PHARMACEUTICALS INC         US8673287004         US           NEURALSTEM INC         US64127R4011         US         SWEDISH ORPHAN BIOVITRUM AB         SE0000872095         SE           NEUROGESX INC         US6412521014         US         SYMBIO PHARMACEUTICALS LTD         JP3383050006         JP           NEWLINK GENETICS CORP         US6515111077         US         SYNAGEVA BIOPHARMA CORP         US87159A1034         US           NICHI-IKO PHARMACEUTICAL CO         JP3687200000         JP         TAKEDA PHARMACEUTICAL CO LTD         JP3463000004         JP           NIPPON KAYAKU CO LTD         JP3694400007         JP         TEJIN LTD         JP3544000007         JP           NIPPON SHINYAKU CO LTD         JP3717600005         JP         TESARO INC         US8815691071         US           ALPINE IMMUNE SCIENCES INC         US66737P6007         US         TEVA PHARMACEUTICAL-SP ADR         US8816242098         IL           NOVARTIS AG-REG         CH0012005267						
NEKTAR THERAPEUTICS         US6402681083         US         SUMITOMO DAINIPPON PHARMA CO         JP3495000006         JP           NESTLE SA-REG         CH0038863350         CH         SUNESIS PHARMACEUTICALS INC         US8673287004         US           NEURALSTEM INC         US64127R4011         US         SWEDISH ORPHAN BIOVITRUM AB         SE0000872095         SE           NEUROGESX INC         US6412521014         US         SYMBIO PHARMACEUTICALS LTD         JP3383050006         JP           NEWLINK GENETICS CORP         US6515111077         US         SYNAGEVA BIOPHARMA CORP         US87159A1034         US           NICHI-IKO PHARMACEUTICAL CO         JP3687200000         JP         TAKEDA PHARMACEUTICAL CO LTD         JP3463000004         JP           NIPPON KAYAKU CO LTD         JP3694400007         JP         TEJIN LTD         JP3544000007         JP           NIPPON SHINYAKU CO LTD         JP3717600005         JP         TESARO INC         US8815691071         US           ALPINE IMMUNE SCIENCES INC         US02083G1004         US         TEVA PHARMACEUTICAL-SP ADR         US8816242098         IL           NOVARTIS AG-REG         CH0012005267         CH         MOLECULAR TEMPLATES INC         US6085501095         US           NOVELION THERAPEUTICS INC         CA67001K2020<						
NESTLE SA-REG         CH0038863350         CH         SUNESIS PHARMACEUTICALS INC         US8673287004         US           NEURALSTEM INC         US64127R4011         US         SWEDISH ORPHAN BIOVITRUM AB         SE0000872095         SE           NEUROGESX INC         US6412521014         US         SYMBIO PHARMACEUTICALS LTD         JP3383050006         JP           NEWLINK GENETICS CORP         US6515111077         US         SYNAGEVA BIOPHARMA CORP         US87159A1034         US           NICHI-IKO PHARMACEUTICAL CO         JP3687200000         JP         TAKEDA PHARMACEUTICAL CO LTD         JP3463000004         JP           NIPPON KAYAKU CO LTD         JP3694400007         JP         TEIJIN LTD         JP3544000007         JP           NIPPON SHINYAKU CO LTD         JP3717600005         JP         TESARO INC         US8815691071         US           ALPINE IMMUNE SCIENCES INC         US02083G1004         US         TEVA PHARMACEUTICAL-SP ADR         US8816242098         IL           NORTHWEST BIOTHERAPEUTICS         US66737P6007         US         TG THERAPEUTICS INC         US6085501095         US           NOVELION THERAPEUTICS INC         CA67001K2020         CA         THROMBOGENICS NV         BE0003846632         BE						
NEURALSTEM INC         US64127R4011         US         SWEDISH ORPHAN BIOVITRUM AB         SE0000872095         SE           NEUROGESX INC         US6412521014         US         SYMBIO PHARMACEUTICALS LTD         JP3383050006         JP           NEWLINK GENETICS CORP         US6515111077         US         SYNAGEVA BIOPHARMA CORP         US87159A1034         US           NICHI-IKO PHARMACEUTICAL CO         JP3687200000         JP         TAKEDA PHARMACEUTICAL CO LTD         JP3463000004         JP           NIPPON KAYAKU CO LTD         JP3694400007         JP         TEIJIN LTD         JP3544000007         JP           NIPPON SHINYAKU CO LTD         JP3717600005         JP         TESARO INC         US8815691071         US           ALPINE IMMUNE SCIENCES INC         US02083G1004         US         TEVA PHARMACEUTICAL-SP ADR         US8816242098         IL           NORTHWEST BIOTHERAPEUTICS         US66737P6007         US         TG THERAPEUTICS INC         US6085501095         US           NOVELION THERAPEUTICS INC         CA67001K2020         CA         THROMBOGENICS NV         BE0003846632         BE	NEKTAR THERAPEUTICS	US6402681083	US	SUMITOMO DAINIPPON PHARMA CO	JP3495000006	JP
NEURALSTEM INC         US64127R4011         US         SWEDISH ORPHAN BIOVITRUM AB         SE0000872095         SE           NEUROGESX INC         US6412521014         US         SYMBIO PHARMACEUTICALS LTD         JP3383050006         JP           NEWLINK GENETICS CORP         US6515111077         US         SYNAGEVA BIOPHARMA CORP         US87159A1034         US           NICHI-IKO PHARMACEUTICAL CO         JP3687200000         JP         TAKEDA PHARMACEUTICAL CO LTD         JP3463000004         JP           NIPPON KAYAKU CO LTD         JP3694400007         JP         TEIJIN LTD         JP3544000007         JP           NIPPON SHINYAKU CO LTD         JP3717600005         JP         TESARO INC         US8815691071         US           ALPINE IMMUNE SCIENCES INC         US02083G1004         US         TEVA PHARMACEUTICAL-SP ADR         US8816242098         IL           NORTHWEST BIOTHERAPEUTICS         US66737P6007         US         TG THERAPEUTICS INC         US6085501095         US           NOVELION THERAPEUTICS INC         CA67001K2020         CA         THROMBOGENICS NV         BE0003846632         BE	NESTLE SA-REG	CH0038863350	CH	SUNESIS PHARMACEUTICALS INC	US8673287004	US
NEUROGESX INC         US6412521014         US         SYMBIO PHARMACEUTICALS LTD         JP3383050006         JP           NEWLINK GENETICS CORP         US6515111077         US         SYNAGEVA BIOPHARMA CORP         US87159A1034         US           NICHI-IKO PHARMACEUTICAL CO         JP3687200000         JP         TAKEDA PHARMACEUTICAL CO LTD         JP3463000004         JP           NIPPON KAYAKU CO LTD         JP3694400007         JP         TEIJIN LTD         JP3544000007         JP           NIPPON SHINYAKU CO LTD         JP3717600005         JP         TESARO INC         US8815691071         US           ALPINE IMMUNE SCIENCES INC         US02083G1004         US         TEVA PHARMACEUTICAL-SP ADR         US8816242098         IL           NORTHWEST BIOTHERAPEUTICS         US66737P6007         US         TG THERAPEUTICS INC         US6085501095         US           NOVELION THERAPEUTICS INC         CA67001K2020         CA         THROMBOGENICS NV         BE0003846632         BE						
NEWLINK GENETICS CORP         US6515111077         US         SYNAGEVA BIOPHARMA CORP         US87159A1034         US           NICHI-IKO PHARMACEUTICAL CO         JP3687200000         JP         TAKEDA PHARMACEUTICAL CO LTD         JP3463000004         JP           NIPPON KAYAKU CO LTD         JP3694400007         JP         TEIJIN LTD         JP3544000007         JP           NIPPON SHINYAKU CO LTD         JP3717600005         JP         TESARO INC         US8815691071         US           ALPINE IMMUNE SCIENCES INC         US02083G1004         US         TEVA PHARMACEUTICAL-SP ADR         US8816242098         IL           NORTHWEST BIOTHERAPEUTICS         US66737P6007         US         TG THERAPEUTICS INC         US68322Q1085         US           NOVARTIS AG-REG         CH0012005267         CH         MOLECULAR TEMPLATES INC         US6085501095         US           NOVELION THERAPEUTICS INC         CA67001K2020         CA         THROMBOGENICS NV         BE0003846632         BE						
NICHI-IKO PHARMACEUTICAL CO         JP3687200000         JP         TAKEDA PHARMACEUTICAL CO LTD         JP3463000004         JP           NIPPON KAYAKU CO LTD         JP3694400007         JP         TEIJIN LTD         JP354400007         JP           NIPPON SHINYAKU CO LTD         JP3717600005         JP         TESARO INC         US8815691071         US           ALPINE IMMUNE SCIENCES INC         US02083G1004         US         TEVA PHARMACEUTICAL-SP ADR         US8816242098         IL           NORTHWEST BIOTHERAPEUTICS         US66737P6007         US         TG THERAPEUTICS INC         US88322Q1085         US           NOVARTIS AG-REG         CH0012005267         CH         MOLECULAR TEMPLATES INC         US6085501095         US           NOVELION THERAPEUTICS INC         CA67001K2020         CA         THROMBOGENICS NV         BE0003846632         BE						
NIPPON KAYAKU CO LTD         JP3694400007         JP         TEIJIN LTD         JP3544000007         JP           NIPPON SHINYAKU CO LTD         JP3717600005         JP         TESARO INC         US8815691071         US           ALPINE IMMUNE SCIENCES INC         US02083G1004         US         TEVA PHARMACEUTICAL-SP ADR         US8816242098         IL           NORTHWEST BIOTHERAPEUTICS         US66737P6007         US         TG THERAPEUTICS INC         US88322Q1085         US           NOVARTIS AG-REG         CH0012005267         CH         MOLECULAR TEMPLATES INC         US6085501095         US           NOVELION THERAPEUTICS INC         CA67001K2020         CA         THROMBOGENICS NV         BE0003846632         BE						
NIPPON SHINYAKU CO LTD         JP3717600005         JP         TESARO INC         US8815691071         US           ALPINE IMMUNE SCIENCES INC         US02083G1004         US         TEVA PHARMACEUTICAL-SP ADR         US8816242098         IL           NORTHWEST BIOTHERAPEUTICS         US66737P6007         US         TG THERAPEUTICS INC         US88322Q1085         US           NOVARTIS AG-REG         CH0012005267         CH         MOLECULAR TEMPLATES INC         US6085501095         US           NOVELION THERAPEUTICS INC         CA67001K2020         CA         THROMBOGENICS NV         BE0003846632         BE						
ALPINE IMMUNE SCIENCES INC US02083G1004 US TEVA PHARMACEUTICAL-SP ADR US8816242098 IL NORTHWEST BIOTHERAPEUTICS US66737P6007 US TG THERAPEUTICS INC US88322Q1085 US NOVARTIS AG-REG CH0012005267 CH MOLECULAR TEMPLATES INC US6085501095 US NOVELION THERAPEUTICS INC CA67001K2020 CA THROMBOGENICS NV BE0003846632 BE						
NORTHWEST BIOTHERAPEUTICS US66737P6007 US TG THERAPEUTICS INC US88322Q1085 US NOVARTIS AG-REG CH0012005267 CH MOLECULAR TEMPLATES INC US6085501095 US NOVELION THERAPEUTICS INC CA67001K2020 CA THROMBOGENICS NV BE0003846632 BE						
NOVARTIS AG-REG CH0012005267 CH MOLECULAR TEMPLATES INC US6085501095 US NOVELION THERAPEUTICS INC CA67001K2020 CA THROMBOGENICS NV BE0003846632 BE					US8816242098	
NOVELION THERAPEUTICS INC CA67001K2020 CA THROMBOGENICS NV BE0003846632 BE	NORTHWEST BIOTHERAPEUTICS	US66737P6007		TG THERAPEUTICS INC	US88322Q1085	
NOVELION THERAPEUTICS INC CA67001K2020 CA THROMBOGENICS NV BE0003846632 BE	NOVARTIS AG-REG	CH0012005267	CH	MOLECULAR TEMPLATES INC	US6085501095	US
	NOVELION THERAPEUTICS INC	CA67001K2020	CA	THROMBOGENICS NV	BE0003846632	

TORAY INDUSTRIES INC	JP3621000003	JP	AUDENTES THERAPEUTICS INC	US05070R1041	US
TRANSGENE SA	FR0005175080	FR	BEIGENE LTD-ADR	US07725L1026	CN
UCB SA	BE0003739530	BE	BRAINSTORM CELL THERAPEUTICS	US10501E2019	US
ULTRAGENYX PHARMACEUTICAL IN	US90400D1081	US	CASCADIAN THERAPEUTICS INC	US14740B6065	US
UNIQURE NV	NL0010696654	NL	CORBUS PHARMACEUTICALS HOLDI	US21833P1030	US
UNITED THERAPEUTICS CORP	US91307C1027	US	DIMENSION THERAPEUTICS INC	US25433V1052	US
VALEANT PHARMACEUTICALS INTE	CA91911K1021	US	DIURNAL GROUP PLC	GB00BDB6Q760	GB
VALNEVA SE	FR0004056851	FR	GALAPAGOS NV	BE0003818359	BE
VECTURA GROUP PLC	GB00B01D1K48	GB	IDERA PHARMACEUTICALS INC	US45168K3068	US
VERASTEM INC	US92337C1045	US	IMMUNOVACCINE INC	CA45254B1031	CA
VERICEL CORP	US92346J1088	US	JCR PHARMACEUTICALS CO LTD	JP3701000006	JP
VERSARTIS INC	US92529L1026	US	MYOKARDIA INC	US62857M1053	US
VERTEX PHARMACEUTICALS INC	US92532F1003	US	NANTKWEST INC	US63016Q1022	US
VICAL INC	US9256022032	US	NORDIC NANOVECTOR ASA	NO0010597883	NO
VIFOR PHARMA AG	CH0364749348	CH	ONXEO	FR0010095596	FR
SHIRE VIROPHARMA INC	US9282411084	US	RA PHARMACEUTICALS INC	US74933V1089	US
WINDTREE THERAPEUTICS INC	US97382D1054	US	REATA PHARMACEUTICALS INC-A	US75615P1030	US
XENON PHARMACEUTICALS INC	CA98420N1050	CA	TIZIANA LIFE SCIENCES PLC	GB00BKWNZY55	GB
XOMA CORP	US98419J2069	US	TORII PHARMACEUTICAL CO LTD	JP3635800000	JP
3745350 CANADA INC	CA9842381050	CA	TRACON PHARMACEUTICALS INC	US89237H1005	US
YUHAN CORP	KR7000100008	KR	WAVE LIFE SCIENCES LTD	SG9999014716	US
ZAFGEN INC	US98885E1038	US	WILSON THERAPEUTICS AB	SE0008293674	SE
ZIOPHARM ONCOLOGY INC	US98973P1012	US	XENCOR INC	US98401F1057	US
ADAPTIMMUNE THERAPEUTICS-ADR	US00653A1079	GB	ZERIA PHARMACEUTICAL CO LTD	JP3428850006	JP
ADMA BIOLOGICS INC	US0008991046	US	LION BIOTECHNOLOGIES INC	US53619R1023	US
ANTARES PHARMA INC	US0366421065	US			